Stephen F. Austin State University

SFA ScholarWorks
Electronic Theses and Dissertations
Summer 7-12-2021

Medication Versus Brain-Based Treatment: Evaluation Treatment
Preferences of Parents of Children with ADHD
Rebecca Recio-Swift
reciorc@jacks.sfasu.edu

Follow this and additional works at: https://scholarworks.sfasu.edu/etds
Part of the Biological Psychology Commons, Child Psychology Commons, Clinical Psychology
Commons, Developmental Psychology Commons, Health Psychology Commons, and the School
Psychology Commons

Tell us how this article helped you.
Repository Citation
Recio-Swift, Rebecca, "Medication Versus Brain-Based Treatment: Evaluation Treatment Preferences of
Parents of Children with ADHD" (2021). Electronic Theses and Dissertations. 399.
https://scholarworks.sfasu.edu/etds/399

This Dissertation is brought to you for free and open access by SFA ScholarWorks. It has been accepted for
inclusion in Electronic Theses and Dissertations by an authorized administrator of SFA ScholarWorks. For more
information, please contact cdsscholarworks@sfasu.edu.

Medication Versus Brain-Based Treatment: Evaluation Treatment Preferences of
Parents of Children with ADHD
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0
License.

This dissertation is available at SFA ScholarWorks: https://scholarworks.sfasu.edu/etds/399

MEDICATION VERSUS BRAIN-BASED TREATMENT: EVALUATING TREATMENT
PREFERENCES OF PARENTS OF CHILDREN WITH ADHD

By

Rebecca C. Recio-Swift, Master of Art

Presented to the Faculty of the Graduate School of
Stephen F. Austin State University
In Partial Fulfillment
Of the Requirements

For the Degree of
Doctor of Philosophy in School Psychology

STEPHEN F. AUSTIN STATE UNIVERSITY
August, 2021

MEDICATION VERSUS BRAIN-BASED TREATMENT: EVALUATING TREATMENT
PREFERENCES OF PARENTS OF CHILDREN WITH ADHD

By

Rebecca C. Recio-Swift, Master of Arts

APPROVED:
__________________________________
Luis Aguerrevere, Ph.D.
Dissertation Director
__________________________________
Laura Cooper, Ph.D., L.P.
Committee Member
__________________________________
Nina Ellis-Hervey, Ph.D., L.P., L.S.S.P.
Committee Member
__________________________________
Elaine Turner, Ph.D., L.S.S.P.
Committee Member
__________________________________
Luis Aguerrevere, Ph.D.
Department Chair

______________________________
Pauline M. Sampson, Ph.D.
Dean of Research and Graduate Studies

Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent
neurodevelopmental disorders across the world. Currently, treatment for ADHD mostly
consists of either medication or behavioral therapy or a combination of both. However,
research has shown that medication used as therapy for the treatment of ADHD has side
effects which parents deem undesirable for their children. Therefore, recent research has
focused on patient and parent preferences. Studies have found that behavioral or other
treatment options may often be chosen over medications. These same studies have
documented the characteristics of parents that prefer certain treatments for their children.
The purpose of this study is to investigate parent treatment preferences as it relates to
medication and brain-based treatment options. The results of a treatment preference survey
describe three groups of parents, Medication-Based, Brain-Based, and Open parents.
Results were also indicative of certain factors that influence parent treatment choice for
their children with ADHD. This study seeks to provide clinicians with a better
understanding of patient and parent preferences, how to navigate presenting new treatment
options, and to provide information on parents’ willingness to choose brain-based or other
treatments for their children.
Keywords: ADHD, medication, parent preferences, brain-based treatment
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Chapter I
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is listed in the Fifth Edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM) as a
neurodevelopmental disorder that presents as persistent behaviors associated with
inattentiveness, hyperactivity, and/or impulsivity (American Psychiatric Association,
2013). When compared to the previous edition of the DSM (i.e., DMS IV), the updated
criteria were broadened and the age of onset was increased to include symptoms in
adolescents and adults to aid in the diagnosis of ADHD in older individuals. This
disorder has been associated with poor academic performance and social and emotional
difficulties in childhood and adolescence with prolonged difficulties in adulthood (Kofler
et al., 2008; Rabiner et al., 2009; Wehmeier et al., 2010).
Prevalence rates as reported by The Center for Disease Control and Prevention’s
(CDC) National Survey of Children’s Health (2019), estimate that 6.1 million children
between the ages of 2 and 17 years old have been diagnosed with ADHD. Of those 6.1
million children, 64% presented with comorbid emotional, behavioral, or conduct-related
disorders. Regarding treatment, 62% were prescribed medication, 47% were in
behavioral treatment for symptoms of ADHD, and 23% were not receiving either
treatment. More specifically, 32.5% of adolescents received medication only, while
29.7% of adolescents received both medication and behavioral treatment. In a review by
1

Danielson et al. (2018), the data from the CDC’s survey was further analyzed into
specific demographics. It was noted that boys, adolescents between the ages of 12 and 17
years old, Black children, non-Hispanic children, children in English speaking
households, children living in homes within the lowest federal income bracket, children
covered by public or both public and private medical insurance, children living in the
Midwest or South, and those in rural areas were more likely to have received or currently
have a diagnosis of ADHD. In comparison to previous years, there was a 57% increase in
children ages 2-5 years old with ADHD.
Treatment for ADHD has consisted largely of medication management, with two
main types of medications, stimulants and non-stimulants, and behavioral treatments.
Research has identified positive effects of medication use, including improvements on
academic performance and behavioral functioning. Studies have also documented the
effectiveness of behavioral treatments for symptoms of ADHD, especially in relation to
long-term organization and planning skills. Behavioral treatments are recommended as
first-line treatments for younger children (i.e., ages 2-5), while combinations of
medication and behavioral therapy are recommended for children over the age of 6
(Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on
Quality Improvement and Management, 2011; Gleason et al., 2007). However, there are
indications that research has generally failed in claiming superiority of one method of
treatment versus the other (Rajeh et al., 2017). Furthermore, there is documentation of the
negative impact of medication management for ADHD, such as loss of appetite,
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insomnia, irritability, development of tic disorders, and misuse and distribution of
medications (Efron et al., 1997; Lerner & Wigal, 2008; Rabiner et al., 2009).
Although medication has dominated the field of ADHD treatment, other
treatments have begun to receive the attention of research. Brain-based therapies, such as
Neurofeedback (N.F.), have been investigated as alternative treatment options for ADHD.
While NF is still considered to be an experimental treatment option for ADHD, research
has found promising results in reducing the severity of ADHD symptoms and improving
academic outcomes after a pre-determined number of sessions. Research has also
suggested that the effects of N.F. last longer than those of medication even after the
discontinuation of treatment (Duric et al., 2012; Gani, 2009). Previous studies have
shown that a considerable number of parents have concerns over ADHD medications as a
treatment option, especially when medication was the only option presented. One study in
particular evaluated parent treatment choice in relation to different treatment components
and found that parents responses fell into two groups, a medication avoidant group where
parents were largely influenced by their desire to avoid medication; and outcomeoriented parents whose choices were influenced by the outcomes they wanted for their
children (Wacshbucsh et al., 2011). Wacshbucsh et al. (2011) strongly emphasized the
importance of studying parent treatment preferences in order to improve the use and
effectiveness of treatments as well as the outcomes for children and their families.
However, the investigators also noted that parent treatment preferences may not be fixed
and could change with the start and continuation of their child’s treatment, which
3

highlights the need to not only assess a parent’s treatment preferences initially in the
treatment process, but also throughout the process. Therefore, assessing the parent
preferences of the treatment of ADHD (e.g., medication based or behavioral based) is an
important area of focus. The purpose of this study is to evaluate parent treatment choice
of ADHD for their child(ren) in regard to medication or brain-based therapy through the
use of a choice task. In this study, parents completed an ADHD knowledge questionnaire
which was used to compare parent choices and their knowledge of ADHD. Then, parents
were asked to read descriptions of two different treatment methods and indicate their
preference on cost, side effects, outcomes, and treatment components.
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Chapter II
Literature Review
Attention Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental
disorder that is seen across cultures and countries all over the world. ADHD is
characterized by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition,
(DSM-5) as a persistent pattern of behaviors related to hyperactivity/impulsivity and
inattention (American Psychiatric Association [APA], 2013). These symptoms must be
present before the age of 12 but must be occurring consistently for at least the most recent
six months. They must interfere with functional performance in at least two major
settings, such as work, school, and home. There must also be a clear disturbance in the
quality of either their occupational, academic, or social functioning, or a combination of
some or all three of these aspects (APA, 2013). In academic settings, ADHD can inhibit a
student’s ability to learn and impair social functioning (DuPaul & Stoner, 2014). Students
with ADHD can demonstrate poor academic performance, experience rejection from their
peers, and have difficulties inhibiting behavioral impulses (Pelham & Waschbusch,
2004). Therefore, ADHD is typically seen in school-aged children due to the demands of
the school environment. The DSM-5 states an individual’s presenting symptoms must not
be better explained by another disorder and cannot co-occur with a psychotic episode or
schizophrenia (APA, 2013). There are three main types of ADHD: Combined
5

Presentation, Predominantly Hyperactive/Impulsive Presentation, and Predominantly
Inattentive Presentation. Symptoms of ADHD can change over time and therefore change
the presentation of symptoms in the individual (APA, 2013). For example, an individual
may experience a combined presentation of symptoms earlier in life, but as an adult may
experience more inattentive symptoms. This highlights the importance of continued
evaluation of the criteria throughout childhood, adolescence, and young adulthood.
According to The Center for Disease Control and Prevention (CDC) in the United
States in 2016, 6.1 million children, ages 2 to 17, had been diagnosed with ADHD. The
CDC’s data also reports that in 2016, 62% of children diagnosed with ADHD were taking
prescribed medication; 47% received behavioral treatment for ADHD, with that
percentage increasing to 60% for children 2 to 5 years old; 23% were not receiving either
treatment; and 64% had other emotional, mental, or behavioral disorders such as conduct
disorder, anxiety, depression, autism, and Tourette syndrome (Danielson et al., 2018).
More specifically, for adolescents, 32.5% received medication only and 29.7% received
both medication and behavioral treatment. In a review by Danielson et al. (2018), the data
from the CDC’s survey was further analyzed into specific demographics. Those that were
more likely to have received or currently have a diagnosis of ADHD were boys,
adolescents between the ages of 12 and 17 years old, Black children, non-Hispanic
children, children in English speaking households, children living in homes within the
lowest federal income bracket, children covered by public, or both public and private,
medical insurance, children living in the Midwest or South, and those in rural areas. In
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comparison to previous years, there was an increase of 57% of children ages 2-5 years
old with ADHD. Further prevalence rates were specified in relation to severity as 14.5%
reportedly presented with severe ADHD, 43.7% presented with moderate ADHD, and
41.8% fell within mild ADHD. Of the sample, 63.8% had a comorbid disorder with
behavioral or conduct-related disorders being most common as 51.5% presented with
behavioral comorbid problems; and 32.7% had anxiety-related difficulties, 16.8%
presented with depressive symptoms, 13.7% had autism spectrum disorder, and 1.2%
presented with Tourette syndrome. In regard to medication use, a large portion of the
sample, 62%, were reportedly currently taking medications, which accounted for 5.1% of
all U.S children ages 2 to 17. The children more likely to be taking medication for the
management of ADHD were non-Hispanic, primarily English speaking, and children
living in the South. Statistical significance was noted among the ages of children taking
medications. Specifically, children 2 to 5 years old were less likely to be taking
medication than school-aged children and adolescents. In regard to behavioral treatment,
46.7% with current ADHD received behavioral treatment. Several demographic
differences were noted within those who received behavioral treatment. Younger
children, boys, black children, and children with public insurance were more likely to
have received behavioral therapy. Southern and Midwestern children in rural areas were
least likely to have received behavioral treatment.
Gender differences in ADHD are evident but not well described in the literature.
Slobodin and Davidovitch (2019) noted that ADHD is more prevalent in boys than in
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girls; however, this could be due to an under-identification of girls with possible ADHD
due to the differences in symptom manifestation across the genders. Specifically,
Biederman and Faraone (2004) found that girls with a diagnosis of ADHD present with
more inattentive symptoms and less hyperactive/impulsive symptoms when compared to
their male ADHD counterparts. Internalizing problem behaviors are usually more
difficult for caregivers and teachers to identify. Boys with ADHD have been shown to
present with comorbid externalizing behaviors and disorders such as conduct disorder,
oppositional defiant disorder, and aggression, which quickly call the attention of
caregivers and teachers as needing intervention or treatment. Slobodin and Davidovitch
indicate that boys are more likely to have been diagnosed and treated for symptoms
related to ADHD than girls. Male-to-female ratios for ADHD can range from 2:1 to 10:1
(Novik et al, 2006; Ramtekkar et al., 2010; Willcutt, 2012). Slobodin and Davidovitch
(2019) noted the lack of appropriate research studying the gender differences in ADHD.
They described that previous studies have failed to include a suitable number of female
participants and heavily relied on subjective measures of ADHD. The results indicated
that parent and teacher reports showed that girls presented with significantly more
inattentive symptoms than boys. However, no gender differences were noted in
symptoms of hyperactivity and impulsivity. When considering objective measures of
ADHD, in this case the Continuous Performance Task (CPT), gender differences were
found as boys had higher impulsivity. However, no differences in performance (i.e., level
of distractibility) were found between boys and girls. Another study by Ragnarsdottir et
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al (2018) sought to find the gender and age differences in social skills in children with
ADHD. Using subjective measures of social behaviors completed by parents and
teachers, research collected social skill information on 592 children ages 5 to 10 and 215
children ages 6 to 10. Results of the study suggested that girls continued to have peer
problems in younger childhood and older childhood, as compared to boys who have more
peer problems in younger childhood. Their data indicated that peer problems in boys
tended to decrease as they got older.
Recent studies on insurance and Medicaid eligibility of children with ADHD have
shown steady increases in children with a diagnosis of ADHD. For example, Nyarko et
al. (2017) describe the prevalence of children with medically managed ADHD and the
differences in those with employer provided insurance coverage and those receiving
public insurance (i.e., Medicaid). The researchers found that the prevalence of ADHD in
children and adolescents with employer-provided insurance increased 2.2% from 2009 to
2015. Rates increased 2% among ADHD children and adolescents with Medicaid in three
years, from 2009 to 2012. These findings were reportedly similar to the studies
investigating raising rates of ADHD diagnosis in general.
Co-morbidity is common in those with ADHD (Jensen et al., 1997). A study
conducted by Bird et al. (1993) provided data on the co-morbidity of ADHD and three
other major diagnostic domains, which were conduct/oppositional disorders, depression
disorders, and anxiety disorders. The data, originally collected for an epidemiological
study on Puerto Rican children ages 4-16, indicated that in the children who met DMS-III
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diagnostic criteria for ADD, 93% presented with comorbid conduct/oppositional
disorders; 26.8% presented with symptoms of a comorbid depressive disorder, and 50.8%
presented with comorbid anxiety disorders. As noted in the review by Jensen et al.
(1997), a study conducted by Cohen et al. (1989) investigated rates of comorbidity
among 93 children with ADD ages 9 to 18 years old, and found that 56% of those
children presented with conduct disorder, 54% presented with symptoms of oppositional
defiant disorder, 23% had an anxiety disorder, 24% had symptoms consistent with
separation anxiety, and 13% presented with major depressive disorder.
According to DuPaul and Stoner (2014), with an average of 20 students in every
classroom in schools across the U.S., at least one student in every class can be or has
been, diagnosed with ADHD. Furthermore, ADHD can impair students’ abilities to
follow instructions, hence affect their schoolwork performance and completion. These
students often have difficulties with organization, test performance, and study skills. In
addition, they frequently disrupt the classroom atmosphere by engaging in impulsive
behavior, such as talking out without permission, disturbing other students during group
and independent work, and becoming expressively angry or frustrated when
consequences for their behavior are given, or when faced with a difficult task (DuPaul &
Stoner, 2014).
Students with ADHD often have difficulty with on-task classroom behavior. A
comprehensive meta-analysis done by Kofler et al. (2008) found that, on average,
students without ADHD are on-task 88% of instructional time, compared to those with
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ADHD who are on-task 74% of instructional time. Studies show these students typically
complete work at a lower rate than their non-ADHD peers, their work is often poor when
compared to other students, and they have significant difficulties with staying on-task
(Davies &Witte, 2000; DuPaul & Langberg, 1990; Frick et al., 1991). These off-task
behaviors lead to a lack of attention to teacher instruction, leading to poor academic
performance.
Difficulties in school performance are not the only problems for students with
ADHD. Wehmeier et al. (2010) summarize the social and emotional difficulties
associated with ADHD. In their review, the authors describe those children with ADHD
tend to have significantly weaker social and communication skills with family and peers
when compared to neuro-typical children and adolescents. Furthermore, since ADHD is
often comorbid with other behavioral disorders, those with comorbidities show to have
greater social impairments than those with ADHD only. Also discussed in the review, is
the emotional impairments of children with ADHD. That is, children and adolescents
with ADHD have poor emotional self-regulation, intense emotional reactions of anger
and aggression, difficulty acquiring adequate coping skills, and poor empathy skills. In
2018, a study by Leaberry et al. sought to find the effect of comorbid internalizing
disorders, and Oppositional Defiant Disorder (ODD) on the emotional regulation of 24
children ages 7 to 10. The researchers measured the children’s respiratory sinus
arrhythmia (RSA), a measure of the parasympathetic nervous system which also manages
stress, as they completed a goal-blocked Card Sorting Task meant to induce stress and
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frustration. The results indicated that children with ADHD and a comorbid internalizing
disorder experienced greater stress and frustration as measured by the RSA when
compared to a baseline phase. This study suggests a physiological component to
emotional regulation in children with ADHD, indicating that the emotional regulation
difficulties children with ADHD have can be linked down to a physiological level.
Physiological mechanisms, such as sleep, are also impacted by children and
adolescents with ADHD. In a review by Hvolby (2015), it was reported that individuals
with ADHD often have difficulties with many aspects of sleep, including but not limited
to, sleep latency, bedtime resistance, shorter sleep time, daytime sleepiness, night
awakenings, and difficulty waking in the mornings. Furthermore, psychopharmacological
treatments for ADHD can often exacerbate these sleep disturbances (Hvolby, 2015).
Understanding the progression of ADHD from childhood into adulthood is vital in
treatment planning, treatment effectiveness, and treatment choice. Research has
documented the progression of ADHD into young adulthood and adulthood. AgnewBlais et al. (2016) documented the persistence, remission, and emergence of ADHD into
young adulthood. Of the participants with ADHD in childhood, 21.1% continued to meet
the diagnostic criteria for ADHD at age 18. Researchers found that continued symptoms
of ADHD were associated with a higher severity of symptoms, lower cognitive abilities
in childhood, higher levels of impairment in functioning, and increased rates of comorbid
disorders at 18 years old when compared to those whose symptoms were in remission.
Agnew-Blais et al. also found that individuals who were diagnosed with ADHD in
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adulthood, did not meet the criteria for ADHD prior to age 12. These individuals were
associated with having fewer behavioral difficulties and higher cognitive abilities at 18
years old when compared to the ADHD persistent group. However, these individuals
presented with similar symptoms, functional impairment, and rates of comorbid disorders
when compared to the persistent group. Faraone et al. (2006) sought to examine the
persistence of ADHD from childhood into adulthood. The study found that although the
persistence of ADHD was highly dependent on the definition of persistence, there was a
high rate of individuals experiencing ADHD “in partial remission” as noted in the DSMIV criteria, as it included about 65% of the sample. However, when the criteria were
restricted to those participants that met full criteria for ADHD, prevalence of persistence
declined to about 15% of the participants. This evidence suggests that symptoms of
ADHD may lessen with age. In a more recent study by Holbrook et al. (2016),
investigated the persistence of ADHD from childhood into adulthood and specified the
role of ADHD presentation in the persistence of symptoms in a community-based
sample. Results indicated that the prevalence of parent-reported inattentive symptoms
counts did not change with age, but the highest count of hyperactivity/impulsivity
decreased with age. Furthermore, individuals with a high count of
hyperactivity/impulsivity and inattentive symptoms (i.e., a combined presentation), were
more likely to continue to experience ADHD symptoms into adulthood. In general, this
study found that those with inattentive symptoms experience more persistence of ADHD
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into adulthood than those with just hyperactive symptoms as results showed a decrease in
parent-reported hyperactivity/impulsivity.
Neural Mechanisms of ADHD
Research has identified that ADHD is caused by multiple factors, such as genetic
and environmental risk factors. Curatolo et al. (2010) reviewed the etiology and
neurobiological basis of ADHD. They cite genetic and environmental contributions on
the development of ADHD. They also found substantial evidence in the association of the
frontostriatal network (i.e., includes the lateral prefrontal cortex, dorsal anterior cingulate
cortex, the caudate nucleus, and putamen), differences in the basal ganglia and other
structures, and changes in cortical thickness in those with ADHD.
A longitudinal study conducted by Shaw et al. (2006) studied the cortical
thickness of 163 children with ADHD and 166 controls and their outcomes. The children
underwent MRI assessment at least twice, once at baseline and again at follow-up.
Outcomes were assessed using the Children’s Global Assessment Scale (CGAS). The
study found that children with ADHD showed a general decrease in cortical thickness,
also referred to as cortical thinning, and, at baseline, those with worse outcomes,
specifically evidenced thinning at the left medial prefrontal cortex. Overall, cortical
thinning in areas responsible for attentional processes, can lead to significantly poor
attentional performance and worse outcomes than individuals with ADHD but minimal
cortical thinning (Shaw et al., 2006).
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A review by Emond et al. (2009) found substantial evidence linking the
frontostriatal network of the brain with deficits in attention, hyperactivity, and
impulsivity. This network encompasses the lateral prefrontal cortex, putamen, dorsal
anterior cingulate cortex, and the caudate nucleus. The review also found growing
evidence of malformations in the lateral ventricles, temporal lobe, parietal lobe, and
occipital lobe of individuals with ADHD. Furthermore, reductions in the size, as
measured by volume of specific brain areas has also been found. Shaw and Rabin (2009)
also found evidence linking abnormalities in the basal ganglia, hippocampus, and
amygdala, as well as the frontostriatal network. In their review, they found that children
with ADHD may experience delays in cortical maturation, which leads to differences in
development and changes in adolescence and on to adulthood.
Medication treatment for ADHD can also alter brain functions, as is its purpose.
For example, Clarke et al. (2001) studied the effects of stimulant medications on the EEG
patterns of children with ADHD. The children’s baseline EEG levels were tested prior to
starting a medication regimen. After a 6-month trail of stimulant medications, a second
EEG was recorded. The researchers found that the ADHD group had significantly higher
delta and theta brain activity prior to the start of stimulant medication. After the 6-month
medication trial, children with ADHD had altered electrical brainwave patterns and
normalized their brain activity.

15

Medication Management of ADHD
The use of medication to manage symptoms of ADHD in children was first
documented in 1937 by Dr. Charles Bradley, who used Benzedrine, also known as
racemic amphetamine, to treat symptoms of hyperactivity and impulsivity (Bradley,
1937). Since then, there has been a sharp increase in medication options for the treatment
of ADHD, most of which consist of methylphenidates and amphetamines (Mayes &
Rafalovich, 2007). This significant increase in medication use has recently been seen in
the U.S. and European countries, where there was at least an 8.8% increase in medication
use in children ages 10 to 14 years old in the years between 2005 and 2012 (Bachmann et
al., 2017). In general, there are two types of medications for ADHD currently available,
stimulant and nonstimulant medications. Within the class of stimulant medications are
different types of stimulants, methylphenidate and amphetamine. Nonstimulant
medications consist of medications that primarily treat other illnesses, but that have
shown to help manage symptoms of ADHD (Southammakosane & Schmitz, 2015).
Stimulant Medications
The American Academy of Child and Adolescent Psychiatry (2013) suggest the
use of stimulant medications as a first-line treatment for symptoms of ADHD. Results
from the Multimodal Treatment of ADHD trial showed decreases in inattention,
hyperactivity, and impulsivity, and improvements in disruptive behavior, academic
performance, and social relationships. Furthermore, stimulant medications have shown to
improve symptoms of depression, narcolepsy, aggression, and defiance (Jensen, 1999).
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A review by Southammakosane and Schmitz (2015) sought to outline the
medications commonly prescribed for ADHD and provide detailed information on the
components of the medications and prescribing practices. They note that stimulant
medications can be broken down into two different groups, long-acting and short-acting.
Within the methylphenidates, a long-acting group, are drugs such as Focalin, Concerta,
Ritalin, Metadate, Methylin, Daytrana, and Quillivant. Focalin, Ritalin, and Methylin are
also noted in the short-acting drugs. The long-acting amphetamines include Vyvanse,
Adderall, and Dexedrine. Short-acting amphetamine drugs include, Adderall,
Dextroamphetamine, and ProCentra.
Stimulant medications have been approved by the Food and Drug Administration
(FDA) since April 2000, for use in children as young as 6-years-old, with certain
amphetamines and dextroamphetamines having been approved for children as young as
3-years-old. Generally, ADHD medications are prescribed starting with a lower dose and
titrating as needed. Furthermore, if the desired response to the drug is not achieved,
physicians can change the stimulant class starting with the same dosage and titrating until
desired effect is maintained (Southammakosane & Schmitz, 2015; Stevens et al., 2013).
Nonstimulant Medications
Nonstimulant medications for ADHD usually consist of medications that are
primarily used for the treatment of other conditions, with the exception of atomoxetine.
These medications can be classified into six different classes: tricyclic antidepressants,
non-tricyclic antidepressants, specific norepinephrine reuptake inhibitors, alpha-2
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noradrenergic agonists, non-schedule stimulants, and others (Budur et al., 2005).
Commonly prescribed for the management of hypertension, central a-agonists
medications, guanfacine, and extended-release clonidine, have been found to be effective
treatments for ADHD. These medications have been approved by the FDA for use in
children as young as 6 years old. Southammakosane and Schmitz (2015) note that the use
of alpha 2 agonists has shown reductions in defiant, hyperactive, and impulsive
behaviors, and improvements in focus and sleep. However, prescribing practices of
alpha-2 agonists require strict adherence to prescription instructions due to the potential
of dangerous hypo- or hyper-tension reactions. Furthermore, with medications such as
clonidine, administration of the drug at night is recommended due to its sedating effects.
Atomoxetine, also known as Strattera, is a norepinephrine reuptake inhibitor
created specifically for the treatment of ADHD. Banaschewski et al., (2004) described
atomoxetine as a “highly selective inhibitor of the presynaptic noradrenaline transporter”
(p. 103). Although this drug has been approved for children as young as 6-years-old and
has been shown to be effective for the ADHD population, a meta-analysis conducted by
Schwartz and Correll (2014) found its effects inferior to that of stimulants and
guanfacine. The most commonly prescribed nonstimulant medications are guanfacine,
clonidine, and atomoxetine.
Positive Effects of Medication Management for ADHD
The results of medication for the management of ADHD can show drastic
changes in children’s behavior and academic performance. A recent meta-analysis,
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including 40 studies on the effects of ADHD medications on functional outcomes,
indicated that medication management of ADHD significantly lowered rates of mood
disorders, suicidality, criminal behaviors, substance use, injuries and accidents, and
traumatic brain injuries; and had a positive effect on educational performance (Boland et
al., 2020).
In a meta-analysis of double-blind placebo-controlled randomized trials with
amphetamines or methylphenidates versus placebos, the authors sought to find the
efficacy of these two medications for children and adolescents diagnosed with ADHD.
Results of the analysis found that amphetamines significantly improved all ADHD
symptomology over methylphenidates in children and adolescents. However, the study
also noted significant publication bias in studies of methylphenidates, but not in those
done on amphetamines (Faraone & Buitelaar, 2010).
A systematic review and meta-analysis by Kortekaas-Rijlaarsdam et al. (2019)
investigated the effects of methylphenidates on academic performance and accuracy in
math, reading, and spelling. Analyses were conducted on thirty-four studies exploring the
effects of methylphenidates on academic productivity and accuracy. All studies also
included a placebo-controlled cross-over design. When compared to placebo groups,
methylphenidates significantly improved accuracy and productivity in math. In reading,
results indicated significant improvements in reading accuracy but not in productivity.
Results were inconclusive for spelling accuracy and productivity. The researchers also
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found that improvements in academic performance were small compared to overall
improvement of ADHD symptoms in children prescribed methylphenidates.
Mikós et al. (2019) sought to study the executive function and attentional
performance in children with ADHD compared to neuro-typical children. Three groups of
participants were identified: medicated children with ADHD, treatment naïve children
with ADHD who had never been treated with methylphenidate or atomoxetine, and
neuro-typical children. Children receiving medication treatment for ADHD were
prescribed methylphenidate or atomoxetine. Results indicate that the performance of
medicated children was more closely aligned to that of the neuro-typical children, as no
significant differences between their performances were found. However, treatment naïve
children with ADHD generally performed worse on tasks of attention and executive
functioning.
Negative Effects of Medication Management of ADHD
Medication management of ADHD has shown significant improvements in
symptoms and performance in children. However, with those improvements, studies have
also documented the side effects and consequences of medication management. A study
conducted by Efron et al. (1997) found that children prescribed methylphenidate and
dexamphetamine were reported to experience insomnia, appetite suppression, irritability,
tearfulness, anxiousness, sadness, and nightmares more so than prior to the start of
medication. Furthermore, Banaschewski et al. (2004) found the following as possible side
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effects: difficultly sleeping, loss of appetite, vomiting, nausea, fatigue, mood swings,
dizziness, and constipation.
Lerner and Wigal (2008) reviewed the most recent studies on the safety of longterm stimulant use for management of ADHD symptoms. They reviewed articles which
investigated the most common side effects of stimulant medication such as
cardiovascular effects, growth, development of tic disorders, carcinogenic evidence, and
effects on reproductive health. Overall, the review states that the studied negative longterm effects of stimulant medications (i.e., elevated blood pressure, stunted growth, and
development of tic disorders) were clinically significant for a minority of the participants
prescribed stimulant medications.
In 2015, Kidwell et al. conducted a meta-analysis to search the literature for the
effects stimulant medications have on the sleep quality of children and adolescents with
ADHD. The researchers specifically focused on children’s sleep latency, sleep efficiency,
and total sleep time. The analysis included a total of nine randomized controlled trial
studies that contained objective measures of sleep (i.e., actigraphy or polysomnography).
The results found significant effects of stimulant medication on sleep latency as stimulant
medication use was associated with longer sleep latency. Furthermore, results also
indicated that medication dosage frequency was a moderator of sleep latency, suggesting
that the more frequently the medication was taken throughout the day, the longer the
sleep latency. Regarding sleep efficiency, the use of stimulant medications had a
significant negative impact on sleep efficiency. However, the longer the use of the
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medication the less negative the effect. Lastly, concerning total sleep time, there was a
moderate effect between stimulant medication and total sleep time, indicating that
children on stimulant medications experience shorter sleep time.
Recent research has begun to show low strength of evidence for the use of
psychopharmacological treatment of ADHD across all ages. A systematic review
conducted by Charach et al. (2011) at the Agency for Healthcare Research and Quality
found a low strength of evidence for the prescription of methylphenidate to 114 preschool
children identified as at-risk for developing ADHD, and a presence of adverse effects on
the children. Moreover, the researchers found low strength of evidence on the use of
methylphenidate and atomoxetine for the reduction of ADHD symptoms and the presence
of adverse effects. The 2018 update to this systematic review was unsuccessful at adding
to the 2011 findings, indicating that the data has no changed significantly (Kemper et al.,
2018).
Another issue that is evident in the use of medications for the treatment of ADHD
is the non-prescribed or unintended use of stimulant medications. In the last decade,
research has addressed the significant misuse of ADHD medications by college students
as well as the self-treatment of attention problems by college students. Rabiner et al.
(2009) examined the misuse and distribution to peers of prescribed ADHD medications.
Participants consisted of 3,407 college undergraduates that were asked to complete a
web-based survey. Of the 3,407 students, 156 students indicated that they had been
diagnosed with ADHD; 115 of those diagnosed were prescribed ADHD medication. The
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study shows that of the 115 students prescribed ADHD medications, 31% indicated
taking their medication more often than prescribed, at a higher dose than prescribed, or
using someone else’s medication. Regarding diversion of medications, 56% of the 115
students with prescriptions reported being approached by other students to sell or give
them their medication and 26% reported giving or selling their medications in the
previous six months. These negative effects of ADHD medications have created
impactful changes in the treatments available for ADHD and in the public perception on
medication use.
Assessing ADHD Through Brainwave Patterns
Quantitative Electroencephalogram (QEEG)
Electrical brain wave speed is measured by hertz (i.e., electrical frequency cycles
per second) and they are divided into bands to delineate slow, moderate, and fast waves
(Hammond, 2011). The four most researched brain wave bands are: Beta waves, Alpha
waves, Theta waves, and Delta waves. Beta waves, measured at 12-30Hz, are the smallest
and the fastest brainwaves associated with an alert state of mind; Alpha waves, measured
at 7-12Hz, are characterized by slower and larger waves than Beta, and are associated
with being in a relaxed state of mind. Alpha waves are known to be prominent in the
posterior and occipital regions of the brain. Theta waves, measured at 4-8Hz, are
characterized by slower and even larger waves than Alpha, and are associated with a
dream-like state or mental inefficiency. Finally, Delta waves, measured at less than 4Hz,
are the slowest and largest waves and are most prominent during deep sleep.
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QEEG Indicators of Neurodevelopmental Disorders
QEEG indicators have been shown to be useful for the assessment of
neurodevelopmental disorders because of the close association between behavior and
EEG frequency (Snyder & Hall, 2006). For example, in clinical settings, QEEG has been
used to identify children with ADHD (Loo & Barkley, 2005). QEEG indicators have
shown that children with ADHD have greater theta activity and lower beta activity in the
brain’s frontal regions than their non-ADHD peers when their eyes are open (Chabot et
al., 2001) or when completing a task (Monastra et al., 2001).
A study conducted by Monastra et al. (1999) focused on the use of QEEG for
assessing the presence of ADHD in 482 participants. The researchers gave traditional
ADHD assessments to identify those with ADHD, then separated participants into three
groups: ADHD inattentive, ADHD combined, and control. Monastra et al. (1999) found
that QEEG correctly identified 86% of the individuals who were found to have ADHD
through the traditional assessments, while correctly detecting 98% of those who were not
ADHD.
Similarly, Clarke et al. (2001) investigated the presence of brainwave differences
in a sample of 184 male children with ADHD. Participants were given full clinical
assessments for ADHD then completed an eyes-closed resting state EEG using the
international 10/20 system. Results indicated consistencies with past studies (Callaway et
al., 1983; Clarke et al., 1998) as the ADHD group had an increase in theta and a decrease
in relative alpha activity, an increase in theta/beta ratio, a decrease in frontal delta, and
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increased frontal and central total power. The cluster analysis indicated three distinct
groups of children with ADHD-C. Cluster 1 showed increased amplitude of theta activity,
particularly in the frontal regions, while also showing a decrease in the amount of delta
and beta activity. Cluster 2 demonstrated high levels of slow wave activity in delta and
theta bands, with reduced fast wave activity. The largest differences between Cluster 2
and the control group were found in the posterior and central regions. In Cluster 3,
analysis indicated high power beta activity with decreased delta and alpha activity. In a
previous study by Clarke et al. (2002), it was found that children with high levels of beta
were more likely to have temper tantrums compared to other ADHD children with a
profile of increased theta. Therefore, attention can be measured and identified using
QEEG indicators, and these indicators have the capacity to reliably differentiate
individuals that have attention disorders from those who do not.
Neurofeedback and ADHD
Neurofeedback (N.F.), or EEG Biofeedback, is the process of retraining brain
wave patterns through operant conditioning (Hammond, 2011). N.F. uses frequency
training, which involves single-channel referential or sequential EEG records at a predetermined number of electrode sites (Hammond et al., 2004). During training, patients
watch a display on a computer screen and listen to feedback audio tones, which signal the
reaching of a goal set by the experimenter (Hammond, 2005). Through this training,
patients can adapt their brain waves into different electrical frequencies (Blanchard &
Epstein, 1978; Heinrich et al., 2007; Kraft, 2006; Masterpasqua & Healey, 2003).
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It has been suggested that through N.F. training, some individuals with ADHD are
able to gain self-control over physiological functions that are not usually consciously
perceived (Heinrich et al., 2007). However, N.F. is still considered an experimental
treatment option for this condition. In a study done by Bakhshayesh et al., (2011) it was
hypothesized that the improvements in the N.F. group would exceed those in the control
group by measuring behavioral changes, as rated by parents and teachers, and
improvements in cognitive performance tests. Also, those in the N.F. group would show
decreased activity in theta and increased activity in beta waves, which are two of the most
important brainwaves in those with ADHD. Thirty-eight children with ADHD, ages 6 to
14, were recruited for the study and randomly assigned to either the neurofeedback group
or control group. Treatment for both groups lasted for 10-15 weeks. Children in the N.F.
group were training on increasing beta and decreasing theta frequencies with electrodes
placed in CPz and FCz. The control group consisted of an alternative type of biofeedback
training using electromyography (EMG) with electrodes placed on the frontalis
musculature for EMG amplitude measurement. Analysis indicated that the overall results
of the parent and teacher rating scales show significant improvements in ADHD related
behaviors after treatments on all subscales of the parent ratings and in three of four
subscales of the teacher ratings. However, Bakhshayesh et al., (2011) stated that they
were unable to prove whether N.F. training was superior to EMG training when studying
hyperactivity and impulsivity symptoms on rating scales.

26

Lévesque et al. (2006) investigated the effects of N.F. training in children with
ADHD on the neural substrates of the selective attentional processes involved in the
Counting Stroop task. Participants were 20 children with ADHD randomly assigned to
either the experimental group or control group. Those in the experimental group (N=15)
received N.F. training, which consisted of enhancing beta amplitude and decreasing theta
amplitude in phase one. In phase two, participants were trained to inhibit theta amplitude
and increase the amplitude of beta waves. Participants in the control group (N=5)
received no treatment. Results were presented in terms of pre- and post-test results. In
Time 1, data were collected on the Counting Stroop task one week before training. In
Time 2, data were collected from the Counting Stroop task one week after the training
was concluded. It was shown that there were no significant differences between the
groups in Time 1 when assessing average scores on Digit Span, The Connors Parent
Rating Scale – Revised (CPRS-R), and the Integrated Vision and Auditory Continuous
Performance Test (IVA). At Time 2, scores of those in the control group were not
significantly different than their own scores in Time 1. However, for those in the
experimental group, scores on the Digit Span and IVA were significantly higher, and
scores on the Inattention and Hyperactivity domains of the CPRS-R were significantly
lower at Time 2.
Gani (2009) presented the first randomized long-term follow-up study that
provided data from N.F. sessions two years after the termination of treatment. Gani
(2009) sought to find whether 1) after 2 years participants were able to maintain the
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ability to self-regulate cortical activation, and 2) whether improvements in attention lead
to differences in the stability of cortical self-regulation and clinical effects. During
treatment, participants were randomly placed in two groups: Slow Cortical Potential
(SCP) group and Theta/Beta group. At the two-year follow-up, participants in both
groups were administered a N.F. session which involved a game with various trials in
place. Generalization trials were implemented into the study to foster practice of selfregulation in daily life, where no continuous feedback was provided during the session,
only after the game was over. Results yielded significant findings in the Theta/Beta
group; children who did not participate in the two-year follow-up exhibited significantly
higher rates of ADHD symptoms than those who did participate. Results of behavior
showed that the number of DSM-IV criteria for both inattention and hyperactivity
declined significantly at the two-year follow-up.
Lansbergen et al. (2011) conducted a pilot study to test the safety and feasibility
of using a double-blind placebo feedback-controlled design in studying the effects of
individualized N.F. training on children with ADHD. Fourteen children, ages 8-15 years
old, completed the study where eight children were randomly assigned to the EEG group
and six assigned to the placebo group. Since N.F. training was individualized, protocols
were determined based on visual inspection of the participants’ QEEG recording prior to
treatment. Feasibility was assessed by adherence to attendance to the study and training
sessions completed. Also, parents and children were asked whether they thought the child
received N.F. training or a placebo. The safety of this design was measured by having
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parents and children complete the Pittsburgh Side Effects Rating Scale (PSERS) before
training and after 6, 10, 20, and 30 training sessions. The Sleep Disorders Questionnaire
was used to assess for sleep problems. Efficacy of the training was measured by the total
severity of inattention and hyperactivity/impulsivity symptoms, which were rated before
training, during training, and 6 months after the termination of treatment. Results showed
that all 14 children completed the study, and 2 out of 6 children and their parents, as well
as one other child but not their parent, in the placebo group thought they received the
N.F. training. Of the remaining children and parents, 75% in the active treatment group
and 50% in the placebo group thought they received placebo training, which suggests that
providing a placebo training as a control condition could be a feasible option to test the
feasibility of N.F. When analyzing safety, neither of the conditions presented significant
adverse side effects on sleep, suggesting that N.F. and a placebo training condition can be
safe approaches. Although there was clinical improvement over time in ADHD
symptomology, there were no significant differences between the EEG N.F. training
condition and the placebo training condition. This suggests that individualized N.F.
training did not exceed the placebo training group in clinical improvement on ADHD
DSM-IV symptomology.
Duric, Assums, Gundersen, and Elgen (2012) recognized the immense lack of
controlled studies, stating that while other studies used other treatments or waitlists as
control groups, randomized control studies are still needed in the field. The objective of
the study was to investigate the effectiveness of N.F. on the core symptoms of ADHD,
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including attention and hyperactivity. Participants were 91 children and adolescents, ages
6-18, with a diagnosis of ADHD. Participants were randomly assigned to either the
neurofeedback group, N.F. plus medication group, or only medication group. Those in
the N.F. group were training to enhance beta and inhibit theta. Sessions were done three
times a week, lasting 40 minutes, with 30 sessions for each participant. The pre- and postevaluations consisted of five-minute baseline periods in the form of alpha training. In the
N.F. plus medication group, neurofeedback protocols were identical to the neurofeedback
group protocols. The medication taken in the N.F. in addition to medication group and
medication only groups was 1 mg of methylphenidate taken twice per day as
recommended. Parent reports showed an improvement in the core symptoms of ADHD in
the N.F. group. Those in the N.F. plus medication group showed similar improvements.
N.F. had an effect on improving attention and hyperactivity symptoms in the participants.
No significant differences were found among the three treatment groups in the
improvement of core symptoms of ADHD, suggesting that the effects of N.F. can be
close to that of stimulant drugs. This study supports the use of N.F. as a less invasive
treatment option for those with ADHD, especially the 20% of the ADHD population that
do not respond to stimulant medication.
Steiner et al. (2011) investigated the effects of two computerized training
programs on teaching children with ADHD to attend better. Participants were 41 children
with ADHD from two middle schools. They were randomly assigned to a N.F. group
which received two sessions a week: a) the attention training through a standard
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computer format (SCF) group, where the participants completed visual and auditory
activities designed to reduce impulsivity and increase attentiveness, or b) the waitlist
condition, which received no treatment until after the post-intervention assessments were
completed. In the N.F. training group, children were trained to decrease theta frequencies
and increase beta frequencies. The Connors Rating Scales – Revised (CRS-R), the
Behavior Assessment Scales for Children (BASC), and the Behavior Rating Inventory of
Executive Functions (BRIEF) were used as outcome measures. Results were mixed,
showing that students in the waitlist condition reported significant change on the CRS-R
ADHD Index, and those in the SCF condition reported significant change on the BASC
Attention Problems Scale. When analyzing observed behavior, those in the N.F. group
showed a trend toward lower levels of fidgeting and off-task behaviors. However, there
were no significant findings. Parents whose children were in the N.F. condition reported
significant changes on all three CRS-R and the two BASC subscales. In the SCF
condition, parents reported significant changes in the CRS-R Inattention and ADHD
Index, BASC Attention Problems, and BRIEF. Overall, Steiner et al. (2011) show the
difficulty of maintaining reliability when conducting N.F. sessions outside of the clinical
setting.
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Public Perception
Public perception can be defined as a social construct where the opinion of a
group of people is collected by asking for their preference or thoughts on particular topics
and used to create a multitude of services and products (Dowler et al., 2006). Public
perception is assessed in almost every industry worldwide and drives the creation and
modifications of policies, technology, education, and more.
In recent years, research focused on the public perception of mental health across
many ages and cultures. Evaluating public perceptions of mental health treatments can
aid in the marketing, creation, and improvement of potential and existing treatment
methods. Therefore, most of this research has revolved on how to change the negative
perceptions that the public holds concerning individuals with mental health illnesses and
the stigma of seeking services. For example, Gaebel et al. (2006) studied the relationship
between the severity of mental illness and the stigma, or public perception, of that illness.
The researchers analyzed studies that used attitude surveys towards diagnostic labels and
other aspects of mental health. In their review, they found that public perception changed
depending on the diagnostic label and the psychosocial disability.
In 2007, Vogel et al. investigated the links between perceived public stigma and
willingness to seek mental health therapy. The participants consisted of college students
enrolled in a psychology course. Participants completed the Perceived DevaluationDiscrimination scale, Self-Stigma of Seeking Help Scale, Attitudes Toward Seeking
Professional Psychological Help Scale, and the Intentions to Seek Counseling Inventory.
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Results indicated that perceived public stigma is positively associated with self-stigma,
self-stigma is negatively related with individuals’ attitudes concerning counseling, and
the attitudes are positively related to the willingness of individuals to seek therapy. In
other words, as public stigma increases, or becomes more negative, so does self-stigma;
and as self-stigma increases, attitudes or willingness to seek counseling decreases. The
researchers stated that although it is difficult to change public perception of mental health
services, knowledge of the mediators between stigma and willingness to seek help can aid
in the development of alternative, practical, and more efficient treatments.
In an effort to investigate parents’ willingness to use psychiatric medication for
the treatment of mental health illness in children, Pescosolido et al. (2007) found
substantial evidence that parents have significant concerns of the stigma surrounding the
treatment of children with mental health needs. Most of the study’s sample (68%)
indicated that they believe physicians over-medicate children, and 45% reported that a
child with mental health needs would experience alienation or rejection in school. Results
also indicated that 35% of the participants believed parents experience self-stigma as a
result of their child’s mental health needs. The researchers discuss the importance of this
information for the development of future treatment options and for mental health and
medical professionals to be prepared when confronted with skepticism. There are
significant concerns that stigma associated with children’s mental health and the
treatment, especially regarding medication, present as a barrier to seeking and being
willing to engage in mental health treatment.
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Assessing Parent Perception of ADHD
In 2003, a study on parent perceptions and satisfaction with medication for
ADHD found that over half of the sample was hesitant to trying medication management
for their children due to public information on medications. Researchers also found that
parents were generally misinformed on ADHD medication treatment and stated that more
information is needed on perceptions of ADHD medications and the differences among
race/ethnicity, income, and social status (DosReis et al., 2003).
A study by Bussing et al. (2012) investigated the ADHD treatment perceptions of
adolescents, parents, healthcare professionals, and teachers. They studied each group’s
views of two pharmacological and three psychosocial treatment methods and their
willingness to participate in all five treatments. Results indicated that adolescents showed
significantly lower desire to engage in any treatment for ADHD. Parents and healthcare
professionals indicated more willingness towards employing/recommending counseling
than teachers. Regarding the use of short-acting or extended-release ADHD medications,
short-acting medications were associated with negative attitudes. However, extendedrelease medications did not have a negative association. Overall, short-acting medications
were generally viewed more negatively as parents, teachers, and adolescent respondents
associated them with a negative stigma, physiological and psychological side effects, and
a greater possibility of future drug dependence, more so than long-lasting medications.
DosReis et al. (2003) conducted a survey study examining parental perceptions
and satisfaction of stimulants as a treatment for ADHD. This study found that around
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55% of parents were at first hesitant for their child to use medication due to the
information in the media, and 33% reported that they believed too many children are
prescribed medication for ADHD. Parents also reported being more satisfied with their
child’s academic and behavioral improvement more so than any improvements in their
child’s self-esteem.
In 2016, Wymbs et al. used a Discrete Choice Experiment to assess parent
preferences between group parent training or individual parent training programs and
how their preference would affect their participation in the training. The study found that
over half of the sample (58.7%) preferred individual parent training and were more
interested in trainings that would help them understand their child and their problems
with ADHD instead of a training that would solve their child’s problems. 19.4% of
parents in the sample reported being most interested in group parent training programs
that would help them build the skills needed to solve the problems their child
experiences. Of particular interest was the 21.9% of parents that fell in what the study
labeled Minimal Information, meaning the parents did not choose either training option.
These parents reported that their child presented with the highest levels of depression and
most severe mental health concerns. The researchers indicated that their results show a
need to consider alternative therapy formats for parent trainings for families that
experience high levels of stress due to the symptoms of ADHD coupled with other life
factors.
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A study by Fegert et al., (2011) sought to examine parent treatment choice for
their children with ADHD using a Discrete Choice Experiment as it relates to medication.
More specifically, the study was to evaluate what therapy attributes were most important
to parents. The researchers used both qualitative and quantitative measures to assess what
factors influence a parent’s choice. The study analyzed the self-administered surveys of
121 parents of school-aged children. The survey generally assessed what attributes and
outcomes of the treatment were most important to the parents. There were 23 total
attributes included in the Discrete Choice Experiment. However, the attributes were
condensed down to six general attributes. The six attributes were duration of action of the
treatment, whether whole-day or half day; side effects; dosage of the product; discretion
of use of the treatment; emotional situation; and social situation. Results found that
parents assigned importance to all six attributes as they were all statistically significant.
However, the improvement of their child’s social performance was the most important
treatment attribute to the parents surveyed. The second most important attribute was an
improvement in emotional functioning and long-acting effectiveness of medication. The
results also showed that the least important attributes for parents were the side effects of
the treatment as long as they did not interfere with the social and emotional functioning
of their child.
In 2011, Waschbusch et al. examined the treatment preferences of 183 parents of
children with ADHD that were not being treated with medications. Parent preference was
assessed using a discrete choice task where parents were presented with brief descriptions
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of the three treatment choices along with possible side effects and risks. Parents chose the
treatment they would prefer their child to receive. According to the results, parents could
be clustered into two groups, Medication Avoidant (70.5% of parents), who were mainly
driven to avoid medication use for their child, or Outcome Oriented (29.5% of parents),
who were more focused on alleviating their child’s problems. This study also found
specific demographic differences in the groups. Parents in the Outcome Oriented group
were more likely to be single parent, had few years of education, lower socioeconomic
status, higher reported stress, and depression, and had behaviorally challenging children.
Using data simulators, Waschbusch et al., (2011) were able to determine what treatments
parents would likely choose. They found that most parents would have rejected
medication only options and instead heavily considered behavioral treatment only or
combined medications and behavioral treatment options. The results demonstrate that
even when presented with multiple options, parents show a preference for nonmedication treatment.
Summary and Study Rationale
ADHD is associated with a variety of academic, social, and occupational
problems such as difficulties retaining educational information, difficulties controlling
emotional and behavioral impulses, and problems keeping up with daily demands. Since
1937, the use of medication management has been the most widely used treatment for
ADHD. Medications for ADHD include stimulants and non-stimulants, each with their
own drug classes. Stimulant medications (i.e., methylphenidates and amphetamines) are
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the most frequently prescribed and have been associated with positive effects on reducing
ADHD symptomology. Non-stimulant medications (i.e., drugs primarily used to treat
other illness and atomoxetine), have also been found to have similar effects, but not as
potent effects as stimulant medications. However, in the last decade there has been a
plethora of studies focusing on the negative effects of medication treatment for ADHD.
Studies have shown that stimulant medications can have short-term and long-term side
effects that many parents find highly problematic (e.g., sleep disruptions, appetite
suppression, growth impairments, higher probability of substance use later in life, and
mood disruptions).
Due to these undesirable effects of medication management for ADHD, other
treatment options have become available. Brain-based treatment such as N.F. is one of
these options. Although still considered an experimental treatment, a decade of research
has found promising results in reducing ADHD symptomology. Studies have documented
reductions in hyperactivity, impulsivity, and inattention while also being able to maintain
these reductions long after the discontinuation of treatment, with a few “booster sessions”
conducted periodically.
Parent perceptions on the treatment of ADHD indicate a significant gap in the
treatments available, as most parents believe there are limited treatment choices. Studies
show that parents are generally weary of medication management for ADHD, and imply
that some parents feel as if they have very limited choices for the effective treatment of
ADHD. Currently, there are few studies that evaluate parent perceptions of brain-based
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treatment options. Additionally, there is limited research that studies the public
perception of neuromodulation as a treatment option in general. Therefore, the purpose of
this study is to 1) evaluate parent treatment choice of ADHD in regard to medication or
brain-based treatment; 2) to evaluate the viability of brain-based treatment from a parent
perspective; 3) to assess the variables that influence parents’ choices; and 4) to help
clinicians build brain-based practices and aid in the effective marketing of brain-based
treatments to parents of children with ADHD.
Hypotheses
The following are the specific hypotheses that will be tested in this study:
I.

When compared to brain-based treatment, parents will be predominantly
medication oriented due to its low cost, easy administration, and quicker response
to treatment.

II.

Based on the findings by Waschbusch et al. (2011), it is hypothesized that
although insignificant, a large number of parents will fall in the brain-based
oriented group due to a high number of parents that are against medication
management for ADHD.

III.

Parents who score higher on the AKOS-R (i.e., have more knowledge of ADHD)
will be more likely to be medication avoidant.
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Chapter III
Method
Participants
The current study had a total sample of 203 participants. Participants were
recruited via online social media parent groups for children with ADHD (See Appendix
A for list of social media groups used). For this study, 137 parents of children with
diagnosed ADHD inattentive, hyperactive/impulsive, and combined presentations
completed the survey in its entirety. Participants were excluded if they did not complete
the survey in its entirety (N=66). Participants consisted of mostly female caregivers
(97.8%). The majority of the sample’s children (82.5%) were receiving treatment for
ADHD. Age of the parents who participated ranged from 21 years old to 59 years old.
The sample was mostly white (86.1%) and had a bachelor’s degree (35.8%). The majority
of the sample had not been personally diagnosed with ADHD (83.2%). See Appendix B
for descriptive statistics for the study’s sample. In the autoclustering analysis, the best
representation of the sample for the 135 participants was the three-cluster solution.
Measures
A brief demographics survey was presented to assess for possible extraneous
variables, exclusion criteria (i.e., not having a child diagnosed with ADHD), and to
gather demographic information on parents and their children.
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Participants were presented with a survey assessing treatment preferences of
ADHD. Participants had two treatment options to choose from: 1) medication use; and 2)
neuromodulation techniques, specifically Neurofeedback. Participants received The
ADHD Treatment Choice Task for Parents. This task is a modification of the choice task
developed by Waschbusch et al. (2011). The task includes brief descriptions of each of
the treatment components: – describing the techniques and procedures that could be used
in the treatment, and treatment outcomes; – describing any changes that could result from
the treatment, and side effects; and – describing negative effects and costs of treatment
(Appendix C).
The ADHD Treatment Choice Task for Parents was assessed through a pilot study
using 10 doctorate-level graduate students enrolled in a Southwestern university. The
results of this pilot study can be found in Appendix D. The results show that the majority
(90%) of respondents may regret the treatment choice if the child experiences longlasting side effects. Conversely, 60% of respondents reported that short-term side effects
would not make them regret their treatment choice. Half of the sample indicated that they
would spend $50 to $500 a month on long-term treatments, while 10% said they would
spend $1200 a month on treatment, as long as the treatment did not last longer than six
months. In 70% of the respondents, insurance coverage would influence the treatment
choice. Concerning scientific validity, 90% of the sample indicated that they would only
choose a treatment options that has strong scientific evidence. 40% of the sample
reported they would like the treatment to have some sessions with the treatment provider,
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and 60% stated they would like the treatment to include a therapeutic component.
Regarding immediate changes in behavior, 80% of the sample indicated that it is not
important for their child to experience immediate changes, as long as they were assured
that changes would occur later. The majority of the sample (44.4%) reported that when
symptoms are no longer observed, they would prefer their child not need further
treatment other than booster sessions. Regarding child awareness and treatment
components, 90% of respondents stated that it was important for them to choose a
treatment that would help the child become more aware of their condition, 77.7% stated
that their child would take a low dose of medication, and 77.7% also endorsed that their
child would attend some sessions of brain-based treatment.
The Attention-Deficit/Hyperactivity Disorder Knowledge Scale – Revised
(AKOS) was used to assess parents’ knowledge of ADHD and effective treatments. The
AKOS is a 43-item true/false survey designed to measure parent knowledge of and
attitude towards ADHD and various evidence-based treatment options (Appendix C,
Figure 2). Parents completed only the first 17 items as this comprises the Knowledge
Scale (Owen Currier, 2004).
Procedure
After providing their Informed Consent, participants completed a demographics
survey to document if they are a parent of a child with ADHD, their gender, age,
ethnicity, years of education, whether their child is receiving treatment for ADHD, and
whether they as parents have been formally diagnosed with ADHD. After completion of
42

the demographics survey parents completed the AKOS-R where they were asked to
indicate their belief on whether various statements about ADHD were true or false.
Participants were then presented with the choice task which was comprised of
brief descriptions of each treatment option; descriptions included the costs, side effects,
and possible outcomes. Participants choose their preference as it related to side effects,
costs, scientific validity, treatment sessions, therapeutic components, immediate changes,
continuation of treatment, child awareness, and treatment components.
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Chapter IV
Results
Statistical Analyses
The present study is an exploratory design consisting of mixed methods of
quantitative measures (i.e., Cluster Analysis) and qualitative measures (i.e., description
on clusters). To analyze the data of this study’s exploratory design, a variety of statistical
analyses were conducted. Statistical analyses were conducted using the IBM SPSS
program. To reduce Type I error, this study used a p<.05 significance level. Totals and
percentages for the sample were collected and used for overall analyses (See Appendix
B). A Cluster Analysis was conducted to identify potential groups or clusters of parents
within the responses to the Treatment Choice Task for Parents. Cluster Analyses are used
in exploratory research to find groups within data. The groups are not assigned needing in
terms of dependent and independent variables and must be assigned meaning in a
descriptive fashion (Field, 2013). A factor analysis was also conducted on the Treatment
Choice Task for Parents to ensure differentiation between the items within the task.
Factor Analyses aid in identifying whether questions or items of a task or questionnaire
are different or similar to one another. This analysis is important to establish reliably of a
measure’s individual items. For the purposes of this study, the factor analysis also serves
as a method to find consistencies in questions that can be grouped together as shown in
Table 6.
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Cluster Analysis
Defining the Number of Clusters. An exploratory two-step cluster analysis was
conducted using each item of the ADHD Treatment Choice Task for Parents. The
autoclustering function from SPSS was used to find the best cluster solution. The SPSS
autoclustering functioning selects the lowest information criterion measure as the best
solution (the Schwarz Bayesian Information Criterion; BIC) and the highest ratio of
distance measures (RDM; “SPSS 14”, 2005). An Autoclustering solution is affected by
the order of the data (Milligan & Hirtle, 2003). Therefore, the full data set was ordered by
the participants’ IP addresses alternating in an ascending and descending fashion. Results
showed two optimal numbers of clusters, those being the three- and four-cluster
solutions. There was not a substantial difference in variance between the three (BIC =
3872.6) and four (BIC = 3863.1.7; RDM = 1.0) cluster solution. Therefore, the threecluster solution was chosen as the distribution of data is best explained within three
clusters for the three choice options within the ADHD Treatment Choice Task for
Parents.
A Chi-Square analysis aided in explaining if the distribution of the results of this
study (i.e., study’s sample) statistically differed from the expected distribution (i.e.,
population). This analysis was chosen to identify differences between the two categorical
variables in the study (i.e., medication-based or brain-based). Upon inspection of the chisquare results for the three- and four-cluster solutions, the four-cluster solution was
removed from formal analyses as the three-cluster solution best explains the distribution
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of the data. However, the four-cluster solution analyses are provided for review in
Appendix E.
As seen in Table 1, 88.1% of respondents in Cluster 1, 93.5% of respondents in
Cluster 2, and 66.7% of respondents in Cluster three reported that their child was
currently receiving treatment for ADHD, suggesting that Parents in Cluster 3 were less
likely to have their children in treatment for ADHD. Parents in Cluster 2 reported having
their children in treatment more so than parents in Clusters 1 and 3. Furthermore,
although not significant, Cluster 2 had the highest percentage of parents diagnosed with
ADHD (i.e., 22.6%) and parents in Cluster 3 (i.e., 8.9%) were less likely to have been
diagnosed with ADHD themselves. There were no significant differences in education,
gender, and race/ethnicity between the clusters.
Table 1
Chi-Square Demographics Results for the Three-Cluster Solution
Variable

Cluster 1

Cluster 2

Cluster 3

N=59(43.70%)

N=31(22.96%)

N=45(33.33%)

88.1

93.5

18.6

22.6

X2

p

66.7

11.58

.003

8.9

2.95

NS

Child receiving
treatment for
ADHD?
Parent
(participant)
diagnosed with
ADHD/ADD?
Table 1 Continued…
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Variable

Cluster 1

Cluster 2

Cluster 3

N=59(43.70%)

N=31(22.96%)

N=45(33.33%)

10.2

6.5

11.1

16.9

16.1

4.4

28.8

29.0

48.9

25.4

32.3

28.9

18.6

16.1

6.7

Female

98.3

93.5

100

Male

1.7

6.5

0.0

Hispanic

5.1

12.9

8.9

Black

3.4

3.2

0.0

White

89.8

80.6

84.4

Asian

0.0

0.0

4.4

Other

1.7

3.2

2.2

X2

p

10.46

NS

3.65

NS

7.50

NS

Education
Diploma/GED
Associate’s
Degree
Bachelor’s
Degree
Master’s Degree
Doctorate/advan
ced degree
Gender

Race/Ethnicity

Presented in Table 2 are the results of the chi-square analysis on the Treatment
Choice Task for Parents.
Long-Lasting Side Effects: Significant differences between the clusters was
evident at the less than .001 level. Specifically, 86.4% of parents in Cluster 1 reported
that long-lasting side effects may make them regret the treatment choice. In Cluster 2,
47

64.5% reported that the side-effects would not make them regret the treatment choice. In
Cluster 3, while the distribution was slightly more even, 46.7% of parents reported that
long-lasting effects would significantly make them regret the treatment choice.
Short-Lasting Side Effects: Significant differences between the clusters were
noted. In Cluster 1, 57.6% of parents reported they would not regret the treatment due to
short-lasting side effects. In Cluster 2, 61.3% of parents said they would not regret the
treatment due to short-lasting side effects. In Cluster 3, 44.4% of parents reported that
short-lasting effects may make them regret the treatment choice.
Cost: There were significant differences between the clusters at the less than .001
level. In Cluster 1, 72.9% of parents indicated that they would pay $15 to $500 a month
on long-term treatments. In Cluster 2, 71.0% of parents reported that they would pay $15
to $500 a month as well. In Cluster 3, 57.8% of parents reported that cost would not
influence their choice of treatment for their child.
Insurance coverage: There were no significant differences between the clusters. In
all three clusters, the majority of parents (i.e., 76.3% in Cluster 1, 64.5% in Cluster 2, and
71.1% in Cluster 3) reported that insurance coverage may influence their choice of
treatment for their child.
Scientific Validity: There was no significant difference between the clusters. The
majority of parents in all three clusters (i.e., 67.8% in Cluster 1, 87.1% in Cluster 2, and
64.4% in Cluster 3) reported that they would choose a treatment choice with high
scientific validity.
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Sessions with Provider: Significant differences between the clusters were found at
the less than .001 level. In Cluster 1, 93.2% of parents and in Cluster 2 54.8% of parents
wanted their child to have some sessions with the treatment provider. In Cluster 3, 48.7%
of parents wanted weekly sessions with the provider.
Therapeutic Component: There was a significant difference between the clusters.
Within Cluster 1, 84.7% of respondents would like there to be a therapeutic component to
treatment but it is not a requirement. In Cluster 2, 54.8% of parents also would like a
therapeutic component but is not required. In Cluster 3, 57.8% of parents require a
therapeutic component to their child’s treatment.
Immediate Changes: Results indicate a significant difference between the clusters.
78.0% of parents in Cluster 1 indicated that immediate changes are not important if there
is assurance that their child’s behavior will improve. In Cluster 2, 58.1% of parents
reported that immediate changes in behavior are important. In Cluster 3, 80% of parents
also reported that immediate changes are not important if there is assurance that their
child’s behavior will improve.
Continuation of Treatment: Significant differences were noted at the .05
significance level. Across all three Clusters, the majority of parents in each cluster (61.0
%, 38.7%, and 40.0%) reported that they do not want to continue treatment when
symptoms are no longer observed.
Awareness of Condition: Results indicate significant differences between the
group at the .001 level. In Cluster 1, 2, and 3, a majority of parents (76.3%, 93.5%, and
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93.3% respectively) reported that they want their child’s treatment to help their become
aware of their condition of ADHD.
Medication Treatment: A significant difference between the clusters was present
at the less than .001 level. In Cluster 1, 91.5% of parents reported that their child would
likely receive a low dose of medication. In Cluster 2, 51.6% of parents indicated that their
child would likely receive a high dose of medication. In Cluster 3, 68.9% of parents also
reported that their child would likely receive a low dose of medication.
Brain-based Treatment: Results showed significant differences between the
clusters at the less than .001 level. The majority of parents in Clusters 1 and 3, 66.1% and
55.6% respectively, reported that their child would likely complete some sessions of
brain-based treatment. In Cluster 2, 71.0% of parents reported that their child would not
attend brain-based treatment sessions.
Overall, the data shows certain characteristics of parents within each Cluster.
Parents in Cluster 1 fell generally within the middle of the groups as they were more
likely to have their child in treatment when compared to Cluster 3, but less likely than
Cluster 2. Additionally, parents in Cluster 1 were not as likely to be diagnosed with
ADHD than Cluster 2, but more likely than Cluster 3. Concerning side effects, parents in
this cluster reported a possibility of regretting the treatment choice because of longlasting side effects. However, when considering short-lasting side effects, differences
were seen among the parents in Cluster 1, as the majority (56.7%) reported that they
would not regret short-lasting symptoms, while a considerable number of parents (40.7%)
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reported possibly regretting the treatment choice due to short-lasting side effects.
Regarding costs, the majority of parents in Cluster 1 indicated being willing to spend $15
to $500 a month on long-term treatment. However, these parents also reported that
insurance coverage would possibly influence their decision. Most parents in this cluster
wanted some sessions with the treatment provider and for a therapeutic component to be
included, but it is not required for their treatment of choice. Regarding immediate
changes in behavior, parents in Cluster 1 indicated that immediate behavioral changes
were not required if they had assurance of behavioral progress. The majority of parents in
the sample reported that they would want their child to be able to discontinue treatment
after symptoms are no longer present. Most parents in Cluster 1 wanted a treatment that
will help their child be more aware of their ADHD symptoms. However, it is important to
note that many parents (23.7%) in this cluster also indicated that this was not important to
them. Regarding medication treatment, parents in Cluster 1 believed that their child may
receive a low dose of medication (91.5%) and the majority reported being willing to have
their child complete some sessions of brain-based treatment (66.1%). When compared to
the other clusters, the responses of parents in Cluster 1 indicate a general openness to
brain-based treatment. Therefore, parents in Cluster 1 are considered Brain-Based
Parents.
Parents in Cluster 2 were the most likely to have their child in treatment for
ADHD and were also the most likely to have been diagnosed with ADHD themselves.
Regarding side effects, parents in this cluster were mostly not concerned with long51

lasting or short-lasting side effects. Parents in Cluster 2 reported being willing to spend
$15 to $500 a month on treatment with the availability of insurance possibly influencing
their treatment choice. Most parents in this cluster reported wanting some sessions with
the treatment provider with a therapeutic component being welcomed but not seen as a
requirement for their child’s treatment. Parents in Cluster 2 reported that immediate
changes in their child’s behavior were an important factor in their decision. When
considering continuation of treatment, although most parents reported that their child
should not have to continue treatment after symptoms are no longer observed, many
parents also reported that continuation of treatment was not an important factor for them.
Parents in this cluster reported that it was important for their treatment choice to help
their child understand his or her ADHD. Regarding medication, most parents in Cluster 2
indicated that their child may require a high dose of medication and that they would not
receive brain-based treatment. Therefore, parents in Cluster 2 are Medication-Based
Parents.
Parents in Cluster 3 were less likely to have been diagnosed with ADHD and
more likely to not have their children in treatment. Furthermore, regarding side effects,
parents in this cluster were more preoccupied with the side effects of treatments in
general whether short- or long-term. Parents within this cluster were not as concerned
with treatment cost, as they were more likely to not be influenced by cost of treatment.
However, insurance coverage may influence their treatment choice. Cluster 3 parents
seemed to be divided regarding sessions with the treatment provider, as they wanted
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either weekly or some sessions with the provider. However, the majority of parents in this
group reported that a therapeutic component to treatment was a requirement for their
child. For parents in Cluster 3, immediate changes were not important if there was
assurance of improvement in behavior once treatment started and most wanted the
treatment to discontinue after behavior problems were no longer observed. Parents in
Cluster 3 wanted their child’s treatment to help their child become aware of their
condition of ADHD and seemed to be open to the possibilities of medication treatment
options and brain-based treatment. Therefore, parents in Cluster 3, are Open to both
treatment options.
Table 2
Chi-Square Treatment Choice Task for Parents Results for Three-Cluster Solution
Variable

Cluster 1 Cluster 2

Cluster 3

Long-Lasting Side Effects
Long-lasting side effects my

6.8

64.5

24.4

86.4

32.3

28.9

child may experience will not
make me regret the treatment
choice.
The long-lasting side effects my
child may experience may
make me regret the treatment
choice.
Table 2 Continued…
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X2

p

71.81

<.001

Variable

Cluster 1 Cluster 2

The long-lasting side effects my

6.8

3.2

Cluster 3

X2

p

10.53

.032

18.86

<.001

46.7

child may experience will
make me significantly regret
the treatment choice.
Short-Lasting Side Effects
The short-lasting side effects my

57.6

61.3

42.2

40.7

38.7

44.4

1.7

0.0

13.3

child may experience will not
make me regret the treatment
choice.
The short-lasting side effects my
child may experience may
make me regret the treatment
choice.
The short-lasting side effects my
child may experience will
make me significantly regret
the treatment choice.
Cost
I will spend $15 to $500 a month

72.9

71.0

33.3

23.7

25.8

57.8

on long-term treatments.
Cost will not influence my
choice of treatment.
Table 2 Continued…
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Variable
I will spend over $1200 a month

Cluster 1 Cluster 2
3.4

3.2

Cluster 3

X2

p

7.76

NS

6.82

NS

59.60

<.001

48.55

<.001

8.9

on treatment if it is less than 6
months
Insurance Coverage
I will only use treatment options

15.3

16.1

4.4

76.3

64.5

71.1

8.5

19.4

24.4

that are covered by insurance
Insurance coverage may
influence my choice
Insurance coverage will not
influence my choice.
Scientific Validity
Strong scientific validity

67.8

87.1

64.4

Scientific validity may or may

32.2

12.9

33.3

0.0

0.0

2.2

not influence my choice
I will not care about scientific
validity
Sessions with Provider
Weekly sessions with provider

1.7

9.7

48.9

Some sessions with provider

93.2

54.8

46.7

Minimal sessions with provider

5.1

35.5

4.4

Therapeutic Component
Does not matter if treatment has

5.1

32.3

therapeutic component
Table 2 Continued…
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8.9

Variable
Would like it included but not

Cluster 1 Cluster 2

Cluster 3

84.7

54.8

33.3

10.2

12.9

57.8

X2

p

25.52

<.001

10.14

.038

17.72

.001

required
Therapeutic component required
Immediate Changes
Immediate changes in behavior

20.3

58.1

11.1

78.0

38.7

80.0

1.7

3.2

8.9

are important
Immediate changes are not
important if there is
reassurance of behavior
changes
Immediate changes in behavior
are not important
Continuation of Treatment
No more treatment when

61.0

38.7

40.0

30.5

32.3

31.1

8.5

29.0

28.9

symptoms are no longer
observed
Not important if treatment
continues after symptoms are
no longer observed
Important to continue to need
treatment
Awareness of Condition
Treatment to keep child unaware

0.0

6.5

of condition
Table 2 Continued…
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2.2

Variable
Not important for child to be

Cluster 1 Cluster 2

Cluster 3

23.7

0.0

4.4

76.3

93.5

93.3

X2

p

56.64

<.001

27.80

<.001

aware of condition
Treatment to help child be aware
of condition
Medication Treatment
No medication

1.7

0.0

26.7

Low dose of medication

91.5

48.4

68.9

High dose of medication

6.8

51.6

4.4

Brain-based Treatment
No brain-based treatment

2.8

71.0

24.4

Some sessions of brain-based

66.1

29.0

55.6

5.1

0.0

20.0

treatment
40 sessions of brain-based
treatment

A one-way ANOVA was conducted to study Hypothesis three, which states that
parents who score higher on the AKOS, and therefore have more knowledge of ADHD,
are more likely to be medication avoidant. However, as shown on Table 3, there were no
significant differences between the clusters, indicating that knowledge of ADHD does not
influence parent treatment choice. Therefore, given that the results of this one-way
ANOVA were not significant, this study will explore the differences between each
individual AKOS question and the three-cluster solution.
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Table 3
Results of One-Way ANOVA on AKOS Total Score and the Three-Cluster Solution
Variable

Mean

SD

F ratio

p

Cluster 1

42.21

3.99

--

--

Cluster 2

41.23

4.01

--

--

Cluster 3

42.95

4.39

--

--

AKOS Total

42.22

4.15

1.58

.221

A second Chi-Square analysis (Table 4) was completed on each question of the
AKOS and the three-cluster solution to better understand how parents’ responses on the
AKOS were presented within the clusters. The AKOS question 1 was significant at the
.05 level. Parents in Cluster 1 (i.e., Brain-Based Parents) and Cluster 2 (i.e., MedicationBased Parents) believed that most children with ADHD continue to have difficulties with
attention when they become teenagers. However, most parents in Cluster 3 (i.e., Open
Parents) indicated that the statement was false. Question 10 addresses how medication
would impact school performance. Results indicate a significant difference at the .05
level. The Brain-Based Parents and Medication-Based Parents believed the statement was
true, while the Open parents mostly believed it was false. AKOS question 12 states that
psychological treatments are not as effective as medication in reducing symptoms.
Similar to the results stated above, Brain-Based and Medication-Based parents mostly
agreed that the statement was true, while the majority of Open Parents indicated that the
statement was false. Significance was at the .01 level. However, it is important to note
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that almost half of the parents in the Brain-Based cluster believe that this statement is
false. The last question to have significant differences between the clusters, AKOS
question 13, states that medication is not as beneficial after children become adolescents
and adults. Although the majority of parents in all three clusters responded that this
statement is false, there are significant differences within the clusters. Specifically, all
parents in the Medication-Based cluster indicated that the statement is false. However,
responses in Brain-Based and Open clusters were more diverse.
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Table 4
Chi-Square Attention-Deficit/Hyperactivity Disorder Knowledge Scale (AKOS) Results for the Three-Cluster Solution
Variable
AKOS 1: Most children with ADHD

Cluster 1

Cluster 2

Cluster 3

T/F

T/F

T/F

64.4/35.6

64.5/35.5

79.7/20.3

X2

p

42.2/57.8

6.05

.049

96.8/3.2

84.4/15.6

4.76

NS

17.2/82.8

25.8/74.2

20.5/79.5

.92

NS

54.2/45.8

35.5/64.5

53.3/46.7

3.23

NS

have problems with attention when
they become teenagers.
AKOS 2: Children with ADHD can be
OK in some situations and be
distractible and disruptive in others.
AKOS 3: Special diets, like the Feingold
diet, have been scientifically proven to
improve the symptoms of most people
with ADHD.
AKOS 4: Medical tests given in a
psychologists’ office are necessary for
making the diagnosis of ADHD.
Table 4 Continued…
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Variable

Cluster 1

Cluster 2

Cluster 3

T/F

T/F

T/F

66.7/33.3

83.9/16.1

93.2/6.8

X2

p

57.8/42.2

5.76

NS

93.5/6.5

100.0/0.0

3.14

NS

30.5/69.5

22.3/77.4

24.4/75.6

.82

NS

25.4/74.6

29.0/71.0

15.6/84.4

2.24

NS

47.5/52.5

35.5/64.5

46.7/53.3

1.32

NS

AKOS 10: In most cases, medication will 64.4/35.6

77.4/22.6

48.9/51.1

6.57

.037

AKOS 5: Medication often reduces a
child’s tendency to be aggressive with
others at school.
AKOS 6: ADHD may sometimes be
inherited.
AKOS 7: Almost all children with
ADHD meet national and state
standard for learning disabilities.
AKOS 8: Boys and girls have similar
rates of ADHD.
AKOS 9: Children with ADHD are
usually brighter than those without
ADHD.
help a child achieve better grades in
school.

Table 4 Continued…
61

Variable
AKOS 11: There is a medical test that is

Cluster 1

Cluster 2

Cluster 3

T/F

T/F

T/F

17.2/82.8

29.0/71.0

50.8/49.2

X2

p

20.0/80.0

1.73

NS

71.0/29.0

35.6/64.4

9.22

.010

5.1/94.9

0.0/100.0

15.6/84.4

7.30

.026

3.4/96.6

0.0/100.0

4.4/95.6

3.69

NS

very effective in identifying children
with ADHD.
AKOS 12: For most children with
ADHD, psychological treatments are
not as effective as medication in
improving attention and reducing
disruptive behaviors.
AKOS 13: The medication(s) used to
treat ADHD are of little benefit when
children reach adolescence or
adulthood.
AKOS 14: There is reliable evidence that
ADHD is often caused by having too
much sugar in a child’s diet.
Table 4 Continued…
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Variable
AKOS 15: Children who are hyperactive

Cluster 1

Cluster 2

Cluster 3

T/F

T/F

T/F

X2

p

15.3/84.7

3.2/96.8

15.9/84.1

3.27

NS

71.2/28.8

71.0/29.0

82.2/17.8

1.97

NS

44.1/55.9

38.7/61.3

26.7/73.3

3.36

NS

at the age of 3 almost always become
identified as having ADHD by the age
of 7.
AKOS 16: There are new medications
available that are more effective and
safer than previous medications such
as Ritalin.
AKOS 17: The diagnosis of ADHD can
be made if symptoms first develop at
the age of 10.
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Factor Analysis
A Principal components analysis was conducted on the Treatment Choice Task
for Parents. On the basis of the scree test (Figure 1) and the percentage of variance
accounted for by each factor, a five-factor solution was found to be most appropriate.
Component 1 accounted for a total of 15.53% of the variance, component 2 accounted for
a total of 12.19% of the variance, component 3 accounted for a total of 11.79% of the
variance, component 4 accounted for a total of 11.42% of the variance, and component 5
accounted for a total of 9.29% of the variance. A value for loadings of .40 was used as a
cut off for items that did not relate to a component. All 12 items loaded on these five
components with item 12 loading on components 4 and 5 (Table 5). Component 1 was
interpreted to represent specific treatment components, Component 2 was interpreted to
represent side effects, Component 3 was interpreted to represent general costs to the
family, Component 4 was interpreted to represent scientific validity and treatment choice,
and Component 5 was interpreted to represent awareness of condition. Results of the
factor analysis, as seen on Table 5, supported the differentiation of each individual
question on the Treatment Choice Task for Parents, meaning that each question measured
different factors that can influence a parent’s choice in treatment for their child. For
further interpretation of the five factors, a Bartlett’s test (Table 7) indicated statistical
significance at the less than .001 level indicating that the data is suitable for a data
reduction technique. A Varimax rotation was used (Table 8) to evaluate potential
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correlations between the TCT-P items. Correlations were found among the items
pertaining to each factor.
Figure 1
Visual Results of Scree Test

Note. The scree plot presented indicates the number of factors to be use in the principal
component analysis. The cut off to determine the factors must be an Eigenvalue above
1.0. Therefore, five factors will be used.
Table 5
Results of Confirmatory Factor Analysis of the 12-Item TCT-P
Item
LT SE
ST SE

R2
.737
.855
Table 5 Continued…

Factor
2
2
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Cost
.809
3
Insurance Coverage
.734
3
Sci. Validity
.780
4
Sessions
-.678
1
Therapeutic Comp.
.701
1
Immediate Changes
.630
1
Conti. Of Treatment
.494
1
Awareness of Cond.
.899
5
Medication
-.582
4
Brain-Based
.535/-.463
4/5
Note. The Confirmatory Factor Analysis is used to determine which factor each item
corresponds to. LT SE = Long-Term Side Effects; ST SE = Short-Term Side Effects
Table 6
Component Transformation Matrix
Factor
1
2
3
4
5
1
.74
.42
.28
.45
.03
2
-.49
.48
.68
-.10
.25
3
-.06
-.63
.59
.35
-.35
4
.46
-.32
.32
-.67
.37
5
.11
.29
.11
-.46 -.82
Note. 1=Treatment components; 2=Side effects; 3=Costs; 4=Scientific validity and
treatment choice; 5=Awareness of condition
Table 7
Bartlett’s Test
Model X2 246.00***
DF
66
Note. ***p<.001
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Table 8
Relationship Between Items in the TCT-P
TCT-P Items

1

2

3

4

5

6

7

LT SE
ST SE
.36
Cost
.08 .01**
Insurance
4
.16
.10
.32
Coverage
5
Sci. Validity
.06 .00** -.06
.10
6
Sessions
-.18
-.07 -.05* .04*
-.10
Therapeutic
7
.22
.13
.12 -.01** .04* -.40
Comp.
Immediate
8
.20 .00** .10
.10
.03* -.28 .24
Changes
Conti. Of
9
-.03* .05*
-.07
-.09
.06 -.14 .14
Treatment
Awareness
10
.07 .00** .03*
.02*
.05* -.07 .10
of Cond.
11
Medication
-.35
-.13
-.21
-.03*
-.18 .22 -.21
12
Brain-Based
.10
-.10
.07
.01**
.20 -.19 .27
Note. LT SE = Long-Term Side Effects; ST SE = Short-Term Side Effects

8

9

10

11

12

-.23

-

1
2
3

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed)
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.15

-

.07

-.00**

-

-.14
.15

.07
.13

-.09
-.15

Chapter V
Discussion
The present study sought to investigate the factors that influence parent treatment
choice for their children with ADHD when given choices between brain-based treatment
options or medication-based treatment. The study also addresses parents’ views on the
viability of brain-based treatment. Furthermore, it aims to give clarity to clinicians on
their clients’ potential choices and the variables influencing their choices, in order to
better market to and reach parents that are interested in or open to brain-based treatments
for their children.
The study investigated three hypotheses; 1) When compared to brain-based
treatment, parents will be predominantly medication oriented due to its low cost, ease of
administration, and their child’s quicker response to treatment; 2) Based on the findings
by Waschbusch et al. (2011), although insignificant, a large number of parents will fall in
the brain-based oriented group due to a high number of parents that are against the use of
medication for their child’s ADHD; and 3) Parents who score higher on the AKOS-R
(i.e., have more knowledge of ADHD) will be more likely to be medication avoidant.
The results did not support hypothesis one. Medication-Based Parents (i.e.,
Cluster 2) were the smallest cluster, accounting for 22.96% of the sample, with BrainBased Parents (i.e., Cluster 1) being the largest cluster accounting for 43.70% of the
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sample. The results of the autoclustering analysis indicated that the data is best
represented in three clusters. The third cluster (i.e., Cluster 3) aligns with a group of
parents whose responses were more diverse and spread throughout the three answer
options given in each item of The ADHD Treatment Choice Task for Parents. These
parents were deemed as Open to both treatment options.
Results supported hypothesis two as a large, although insignificant, number of the
sample fell within the Brain-Based Parent cluster, given that it was largest cluster in the
sample. Statistically significant differences between the clusters and the responses to The
ADHD Treatment Choice Task for Parents were noted in instances when parents
considered the long-lasting and short-lasting side effects, the cost, sessions with the
treatment provider, the inclusion of a therapeutic component in treatment, immediate
changes in their child’s behavior, the continuation of treatment after the symptoms
subsided, and the inclusion of education of their child’s condition in the treatment.
Results did not support hypothesis 3, as no significant differences were found
between a parent’s total AKOS score and their treatment preference. These results
indicate that a parent having knowledge of ADHD does not necessarily influence their
treatment choice, suggesting that parents’ choices of treatment for their children are best
explained by factors such as cost, side effects, and specific treatment components that
will have a direct impact on their family’s lives. Although hypothesis 3 was not
supported, further analysis of the individual AKOS questions with the three-cluster
solution found results worth discussing. Specifically, significant differences were found
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between the clusters when related to questions about the continued experiences of
symptoms into adolescences and adulthood; the impact of medication on educational
performance and behavioral symptoms; and the benefit of medication use from childhood
into adolescence and adulthood. The results of this analysis closely aligned with the
cluster descriptions of Brain-Based Parents, Medication-Based Parents, and Open Parents
from the analysis of The ADHD Treatment Choice Task for Parents. When compared to
Medication-Based Parents, responses from Brain-Based Parents were generally of the
belief that medication was not as helpful, although it is important to note that most
parents within the brain-based cluster were still in favor of medications (i.e., gave a
“True” response). Similar to the results of The ADHD Treatment Choice Task for
Parents, the Open Parents’ responses on the AKOS were much more evenly distributed
between the answer choices of True or False.
Studies evaluating parent preferences of treatment components for their children
with ADHD have begun to show the importance of parent participation, parent buy-in,
and how they can aid in treatment adherence and effectiveness. Results of this study are
comparable to Wymbs et al. (2016) who evaluated the parent preferences of parent
training format. The majority of their sample indicated that they preferred a training
format that would help them better understand their child and their problems with
ADHD. Similarly, in the present study, the majority of parents fell in the Brain-Based
cluster, indicating that they were most interested in a treatment option that provided them
with at least some sessions that include a therapeutic component, as well as child-focused
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education of ADHD. The present study also had a group of parents whose responses fell
in a middle ground where their choices were not more specifically aligned with one
treatment option over the other. The Open parents in the present study where in contrast
to the study conducted by Wymbs et al., as the Minimal Information parents in their
study were more closed off to parent trainings. The Open parents in this study reveal that
there are groups of parents who are more open to treatment options when considering
specific treatment components and how they fit with the family’s lifestyle in conjunction
with treatment outcomes.
This study is also comparable to the results of Fegert et al., (2011) who found
regarding medication treatment, parents were most interested in a treatment where
effectiveness lasted all-day and improved their child’s emotional and social functioning.
The present study’s results further elaborate on Fegert et al., findings, as the results were
able to differentiate between the type of parents who may respond in this fashion.
Differentiating parents into groups can help practitioners address parent concerns, better
target education, and tailor treatments to fit the family’s needs. As a result, this would
help improve both treatment buy-in and adherence, leading to a higher likelihood of
treatment success.
A study by Corkum et al. (1999) assessed how parent knowledge of ADHD and
their opinions of treatment affected their enrollment and adherence to medication-based
and behavior-based treatments. Parents were given a modified version of the AKOS and
then decided to participate in the 12-month randomized trial of medication or placebo and
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parent training groups or parent support groups. The researchers monitored treatment
enrollment and adherence over the 12-month period. Those remaining in the study at the
end of the 12-month period were given another modified AKOS. Results showed that
when analyzing opinions, parents were more open to nonpharmacological treatments than
pharmacological treatments; a higher score on the AKOS was correlated with more
positive opinions of behavioral-based treatments versus medication-based; and higher
AKOS scores were correlated with enrollment of treatment, adherence to medication or
behavioral-based treatment, and was not related to knowledge of ADHD or opinions of
treatment. Furthermore, after completion of the 12-month treatment trial, parent AKOS
scores increased, indicating more knowledge of ADHD. Similar to Corkum et al., in the
present study, knowledge of ADHD did not have a significant impact of parent treatment
choice. However, Corkum et al. found that parent knowledge of ADHD does affect
treatment enrollment and adherence to the treatment.
The present study used methods similar to the study conducted by Waschbusch et
al., (2011). The researchers used a discrete choice task with descriptions of treatments
and parents chose the treatment they would be mostly likely to choose for their child with
ADHD. Results of the Waschbusch et al. study presented two groups of parents,
Medication Avoidant and Outcome Oriented parents. The present study also found that
parents’ treatment choices and the factors that influenced their choices can categorize
parents into descriptive groups. Furthermore, the present study also determined that when
presented with treatment information and given options, parents were largely predicted to
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choose treatments that focus more on behavioral modification or a combination of
behavioral intervention and medications instead of strictly medication-based treatment.
When considering brain-based treatments, parent perceptions and their
expectations also play an important role. A study conducted by deBeus and Kaiser (2011)
hypothesized that children in a neurofeedback treatment group would experience ADHD
symptoms improved, as measured by parent and teacher rating scales and formal ADHD
assessments using the IVA CPT, when compared to a placebo group. Results indicated
that teacher reports showed improvement in behavior after the neurofeedback treatment.
However, there were no changes in parent ratings between the treatment and placebo
groups. This indicates that parents in the placebo and the neurofeedback treatment
conditions, both, rated their child as improving. deBeus and Kaiser attributed this finding
to an expectancy bias. This highlights the significant role that a parent’s perception plays
in the treatment of their child’s symptoms. This study also shows that parental
expectations can influence a parent’s perception of how effective the treatment is.
Recent clinical practice guidelines as described by Shah et al. (2019), include the
need to evaluate parents’ perceptions concerning treatment, consider their treatment
preferences, and consider the family’s current circumstance and resources in order to
recommend a treatment that best fits their needs, resources, and lifestyle. They stress the
importance of a “therapeutic alliance,” which is done by holding positive regard and
respect for parents’ and families’ opinions and concerns about certain treatments. Shah
and colleagues also address the importance of psychoeducation with parents and their
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children. They recommend an average of two to three sessions of psychoeducation that
are also individualized for the family being served. Specifically, they state that clinicians
should focus on providing detailed information on the core symptoms of ADHD and the
etiological factors of ADHD such as genetic and environment components. They also
recommend addressing parental guilt or shame; prevalent misconceptions of ADHD;
descriptions of pharmacological and nonpharmacological treatment options along with
their risks and benefits, and possible outcomes if treatment is sought or if treatment is
either rejected or inconsistent; and the effect of comorbid disorders if present in the child.
When considering brain-based treatments, many of these topics are addressed in the
multiple sessions with the treatment provider. Clinical practice guidelines were proposed
by Micoulaud-Franchi et al. (2015). In their review, they suggest that, although optimum
spacing has not yet been defined, N.F. is usually completed in 20-30 sessions, once to
three times per week. They also note the importance of continued discussions with the
patient, and for the purposes of this present study, discussions with the family and child.
These discussions should include detailed descriptions of the treatment session before
starting, information to sustain motivation during the session, and an explanation of what
to expect after session completion. These proposed practice guidelines for neurofeedback
therapy allow for optimal therapeutic relationship and rapport building, psychoeducation,
and continued communication with parents and children about how the treatment is
progressing toward their goals, any proposed changes, and overall opinions of treatment
options. The development of clinical guidelines in the field of N.F. is critical to its
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perceived and actual effectiveness; and would, in turn, improve parent buy-in for N.F. as
a treatment option for their children. Furthermore, implementation of set guidelines can
aid in N.F. becoming more widely accessible through more reasonable costs and
insurance coverage, which as noted in the present study cost has a significant influence
on parents’ treatment choices.
This study highlights that when offered information on treatment choices, parents
are more influenced by treatment components, costs, therapeutic sessions, education of
ADHD, and behavioral modification than they are by their knowledge of ADHD. This is
of use to clinicians building a brain-based treatment practice for the purposes of
marketing their treatment, gauging parents’ openness to and/or interest in brain-based
treatments, and understanding the specifics driving treatment choice by parents.
Clinicians can use the information from the present study to educate parents on brainbased treatments and find methods to increase the scientific validity of N.F., increase
access to insurance coverage, and provided more affordable treatment options to parents
for their children with ADHD.
Throughout the course of the study, parent participants expressed concerns with
the survey. Some parents reported starting the survey but not finishing as they believed
that the survey forced answers between two choices (specifically in reference to the
AKOS.) Other parents reported that the wording was either confusing or strongly biased
toward brain-based treatment. Comments from parents suggest that when answering the
survey questions, parents did so in reference to their children’s’ current course of
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treatment, rather than the treatment options described in the survey itself (as designed).
For example, one parent had difficulty answering questions because their child is
currently receiving both behavioral and medication treatment and they could not make an
appropriate choice. These concerns from parents indicates that both the AKOS and
Treatment Choice Task for Parents should be heavily reviewed and modified to limit
perceived and actual bias and to clarify instructions on how the survey should be
completed (i.e., parents are to consider choice options based on the treatments described
in the survey, and not based off of treatments their child currently receives). Regarding
bias, this study may have been influenced by researcher bias, as the primary investigators
have had extensive experience in the research and clinical use of brain-based treatment
techniques. The descriptions may also present a more positive description of
neurofeedback than is warranted. As reported by Micoulaud-Franchi et al (2015),
neurofeedback has not been deemed a therapy that can be used, solely, to treat mental and
brain disorders, but rather in conjunction with other treatments. While they note that
promising results have been found in controlled, randomized, and blinded studies; a
plethora of studies with faulty neurofeedback protocols, lack of appropriate comparison
groups, and lack of control and randomization have made it difficult to study its true
effectiveness. Furthermore, the present study did not document important demographic
information from parents concerning their child’s ADHD (e.g., how long they have
carried the diagnosis). Information on their child’s current treatment, such as whether
they are receiving medication treatment, if so, what type of medication is being used, was
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not collected. Information from parents on their previous experiences with ADHD
treatments whether behavioral or pharmacological were also not included in the
demographic’s questionnaire.
Replication of this study is recommended. Stronger measures should be
implemented to accurately evaluate how parent treatment preferences can affect treatment
efficacy, and to assess parents’ opinions on the feasibility of brain-based treatments. Due
to the frustration parents experienced as they completed the choice task, future studies
should consider including a statement that instructs parents to choose their preferences
based, solely, on the treatment options in the survey, rather than comparing to their
child’s current treatment. Future studies should also evaluate the efficacy of using the
AKOS, as it may not be an accurate representation of an individual’s knowledge of
ADHD. This study recommends that the AKOS be revised or updated to include most upto-date best practices and clinical information. The ADHD Treatment Choice Task for
Parents should also be considered for further revisions to ensure an unbiased measure.
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Appendix A
List of Social Media Parent Groups Used for Survey Distribution
ADDitude – ADHD Support Group for Parents
ADHD/ADD Parent Support Group
ADHD Parent Support
Support Group For Parents Of Kids With ADHD, ODD And Other Behavioral Issue
ADHD Texas Kids Support Group For Parents
Moms With ADHD/ADD Kids
ADHD Parent Nutrition Support Group
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Appendix B
Totals and Percentage Values for Final Sample
Table 1
Descriptive Statistics for the Final Sample (N = 137)
Variable

N

%

134

97.8%

3

2.2%

Highschool Diploma/GED

13

9.5%

Associate degree

18

13.1%

Bachelor’s Degree

49

35.8%

Master’s Degree

38

27.7%

Doctorate/Other Advanced Degree

19

13.9%

White

118

86.1%

Latinx

11

8.0%

Black

3

2.2%

Asian

2

1.5%

Other

3

2.2%

Formally Diagnosed with ADHD

23

16.8%

Child receiving treatment for ADHD

113

82.5%

21-59

--

Gender
Female
Male
Highest Degree Completed

Ethnicity

Parent Age Range
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Appendix C
ADHD Treatment Choice Task for Parents
Descriptions of Treatment Components Presented to Parents
Treatment 1: Medication
Description: There are multiple medication options for the treatment of ADHD.
The two main types are stimulant and non-stimulant medications. Stimulant medications
can be classified in two groups, methylphenidates and amphetamines. Non-stimulant
medications are classified as tricyclic antidepressants, non-tricyclic antidepressants,
specific norepinephrine reuptake inhibitors, and non-schedule stimulants.
Possible Outcomes: According to many research studies and clinical trials,
medication use for management of ADHD symptoms can decrease hyperactivity and
impulsivity and increased focus and concentration for an extended period of time. The
decrease of symptoms can lead to improvements in academic, occupational, and social
performance.
Side Effects: For some individuals medication side effects can be troubling and
long lasting. The most common side effects of stimulant medications include difficulty
falling asleep, decrease in appetite, headaches, stomach aches, irritability or a sudden or
more severe presentation of ADHD symptoms. The most common side effects of nonstimulant medication are mild sleepiness and/or headaches and an increase in
hyperactivity.
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Cost: Most medications are available in generic or name brand form. Depending
on the form chosen, medications can range in monthly costs between $15 to $500 given
that most insurance covers this type of treatment. Medication management typically
requires that the individual use medications for many years.
Treatment Option 2: Brain-Based Treatment
Description: Research has shown emerging but promising results on the use of
brain-based treatment for ADHD. Neurofeedback is one widely researched technique that
consists of training pre-determined brain-wave frequencies using visual or auditory
rewards. A cap is placed on the head which measures electrical frequencies in the brain
and displays the frequencies on a software program.
Possible Outcomes: Brain-based treatment of ADHD, such as Neurofeedback, are
considered “experimental.” Some research has suggested that this technique can create
long lasting changes in the brain that help the individual manage impulses and increase
attention and focus, which can positively influence academic, occupational, and social
performance. Techniques such as Neurofeedback have also been found to increase sleep
quality and mood stability.
Side Effects: The most common side effects of brain-based treatment are mild and
only last for few hours after each session; these include, headaches, dizziness, and
redness at the site of the electrodes.
Cost: Most insurance providers do not cover the cost of brain-based treatments
such as Neurofeedback. The cost of Neurofeedback, per session, can range from $100 to
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$300, about $1200 monthly. Neurofeedback is usually not covered by insurance. Brainbased therapy sessions are not a life-long treatment option. Most clients are able to stop
treatment after 40 sessions or after 5 months but may need “booster” sessions every few
months after the completion on treatment.
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Figure 1
The ADHD Treatment Choice Task for Parents
Side effects:
Long-lasting side effects
(i.e., loss of appetite,
headaches, irritability)
my child may experience
will not make me regret
the treatment choice.

The long-lasting side
effects (i.e., loss of
appetite, headaches,
irritability) my child may
experience may make me
regret the treatment
choice.

The long-lasting side
effects (i.e., loss of
appetite, headaches,
irritability) my child may
experience will make me
significantly regret the
treatment choice.

The short-lasting side
effects (i.e., headaches,
dizziness, redness at
electrode site) my child
may experience will not
make me regret the
treatment choice.

The short-lasting side
effects (i.e., headaches,
dizziness, redness at
electrode site) my child
may experience may
make me regret the
treatment choice.

The short-lasting side
effects (i.e., headaches,
dizziness, redness at
electrode site) my child
may experience will make
me significantly regret
the treatment choice.

Costs:
I will spend $15 to $500 a
month on long-term
treatments for my child.

Cost will not influence
my choice of treatment
for my child.

I will spend over $1200 a
month as long as the
treatment does not last
longer than 6 months.

Insurance coverage may
influence my choice of
treatment.

Insurance coverage will
not influence my choice
of treatment.

Scientific evidence may
or may not influence my
choice of treatment.

I will not care about
scientific evidence.

I will only use a
treatment option for my
child that is covered by
my insurance.
Scientific Validity:
I will only use a
treatment option for my
child that has strong
scientific evidence.
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Treatment Sessions:
I would like my child’s
treatment to require
weekly sessions with the
provider.

I would like the
treatment to have some
sessions with the
provider, but it is not
required.

Therapeutic Component:
It does not matter if my
I would like my child’s
child’s treatment includes treatment to include a
a therapeutic component. therapeutic component,
but it is not required.
Immediate Changes:
It is important that my
child will experience
immediate changes in
behavior after starting
treatment.

I would prefer a
treatment with minimal
sessions with the
provider.

My child’s treatment
must include a
therapeutic component.

It is NOT important that
my child will experience
immediate changes in
behavior after starting
treatment, as long as I get
assurance that benefits
will come later.

It is NOT important that
my child will experience
immediate changes in
behavior after starting
treatment.

Continuation of Treatment:
When symptoms are no
longer observed, it is
important that my child
will not continue
treatment (other than
some booster sessions).

When symptoms are no
longer observed, it is
NOT important if my
child continues to need
treatment.

When symptoms are no
longer observed, it is
important that my child
continue to need
treatment regularly for
many years.

Child Awareness:
It is important that I
choose a treatment that
keeps my child unaware
of his/her condition.

It is not important if my
child is aware of his/her
condition.

It is important that I
choose a treatment that
helps my child be aware
of his/her condition.

My child will get a low
dose of medication.

My child will get a high
dose of medication.

Treatment components:
My child will not get
medication.
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My child will not attend
brain-based treatment
sessions.

My child will attend some
sessions of brain-based
treatment.

My child will not attend
behavioral therapy
sessions

My child will attend some My child will regularly
sessions of behavioral
attend sessions of
therapy
behavioral therapy.
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My child will attend 40
sessions of brain-based
treatment.

Figure 2
ADHD Knowledge and Opinion Survey
AKOS-R
Below is a series of true-false statements. Click True if you believe the state is true or
correct. Click False is you think the statement is false or incorrect.
Note: Please do not search for information on these questions. It is very important to get
your current understanding.
1. Most children with ADHD have problems with attention when they
become teenagers
2. Children with ADHD can be OK in some situations (such as at
home) and can be distractible and disruptive in others (such as at
school).
3. Special diets, like the Feingold diet, have been scientifically proven
to improve the symptoms of most people with ADHD.
4. Medical tests given in a psychologists’ office are necessary for
making the diagnosis of ADHD
5. Medication often reduces a child’s tendency to be aggressive with
others at school.
6. ADHD may sometimes be inherited (passed along in the family).
7. Almost all children with ADHD meet national and state standard for
learning disabilities.
8. Boys and girls have similar rates of ADHD
9. Children with ADHD are usually brighter than those without
ADHD
10. In most cases, medication will help a child achieve better grades in
school
11. There is a medical test that is very effective in identifying children
with ADHD.
12. For most children with ADHD, psychological treatments are not as
effective as medication in improving attention and reducing
disruptive behaviors.
13. The medication(s) used to treat ADHD are of little benefit when
children reach adolescence or adulthood.
14. There is reliable evidence that ADHD is often caused by having too
much sugar in a child’s diet.
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15. Children who are hyperactive at the age of 3 almost always become
identified as having ADHD by the age of 7.
16. There are new medications available that are more effective and
safer than previous medications such as Ritalin
17. The diagnoses of ADHD can be made is symptoms first develop at
the age of 10.
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Appendix D
Results of Pilot Study on the TCT-P
Table 1
Results of Pilot Study on The ADHD Treatment Choice Task for Parents
Percentage of pilot participants responses
Choice Item

Percentage

Side Effects
The long-lasting side effects (i.e., loss of appetite, headaches,
irritability) my child may experience may make me significantly

90%

regret the treatment choice.
The long-lasting side effects (i.e., loss of appetite, headaches,
irritability) my child may experience may make me regret the

10%

treatment choice.
The short-lasting side effects (i.e., headaches, dizziness, redness at
electrode site) my child may experience will make me significantly

30%

regret the treatment choice.
The short-lasting side effects (i.e., headaches, dizziness, redness at
electrode site) my child may experience may make me regret the

60%

treatment choice.
The short-lasting side effects (i.e., headaches, dizziness, redness at
electrode site) my child may experience will not make me regret the
treatment choice.
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10%

Table 1 Continued…
Cost/Insurance Coverage
I will spend over $1200 a month as long as the treatment does not last
longer than 6 months.

10%

Cost will not influence my choice of treatment for my child.

40%

I will spend $15 to $500 a month on long-term treatments for my child.

50%

Insurance coverage will not influence my choice of treatment.

30%

Insurance coverage may influence my choice of treatment.

70%

Scientific Validity
Scientific evidence may or may not influence my choice of treatment.
I will only use a treatment option for my child that has strong scientific
evidence.

10%
90%

Treatment Sessions
I would prefer a treatment with minimal sessions with the provider
I would like my child’s treatment to require weekly sessions with the
provider.
I would like the treatment to have some sessions with the provider, but
it is not required.

30
30%
40%

Therapeutic Component
It does not matter if my child’s treatment includes a therapeutic
component.
My child’s treatment must include a therapeutic component.
I would like my child’s treatment to include a therapeutic component,
but it is not required.

20%
20%
60%

Immediate Changes
It is NOT important that my child will experience immediate changes in
behavior after starting treatment.
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20%

Table 1 Continued…
It is NOT important that my child will experience immediate changes in
behavior after starting treatment, as long as I get assurance that

80%

benefits will come later.
Continuation of Treatment
When symptoms are no longer observed, it is NOT important if my

22.2%

child continues to need treatment.
When symptoms are no longer observed, it is important that my child

33.3%

continue to need treatment regularly for many years.
When symptoms are no longer observed, it is important that my child
will not continue treatment (other than some booster sessions).

44.4%

Child Awareness
It is not important if my child is aware of his/her condition.
It is important that I choose a treatment that helps my child be aware of
his/her condition.

10%
90%

Treatment Component
My child will not get medication.

22.2%

My child will get a low dose of medication.

77.7%

My child will attend 40 sessions of brain-based treatment.

22.2%

My child will attend some sessions of brain-based treatment.

77.7%
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Appendix E
Chi-Square Results for the Four Cluster Solution
Table 1
Chi-Square Treatment Choice Task for Parents Results for Four Cluster Solution
Variable

Cluster 1

Cluster 2

Cluster 3

Cluster 4

N=42

N=28

N=23

N=42

Long-lasting side effects my child
14.3

57.1

47.8

4.8

83.3

0.0

47.8

66.7

me regret the treatment choice.
The long-lasting side effects my
child may experience may make

p

65.95 <.001

Long-Lasting Side Effects
may experience will not make

X2

me regret the treatment choice.
Table 1 Continued…
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Variable

Cluster 1

Cluster 2

Cluster 3

Cluster 4

N=42

N=28

N=23

N=42

2.4

42.9

4.3

28.6

X2

p

53.73

<.001

The long-lasting side effects my
child may experience will make
me significantly regret the
treatment choice.
Short-Lasting Side Effects
The short-lasting side effects my
child may experience will not
make me regret the treatment

78.6

75.0

34.8

23.8

19.0

7.1

65.2

73.8

2.4

17.9

0.0

2.4

choice.
The short-lasting side effects my
child may experience may make
me regret the treatment choice.
The short-lasting side effects my
child may experience will make
me significantly regret the
treatment choice.
Table 1 Continued…
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Variable

Cluster 1

Cluster 2

Cluster 3

Cluster 4

N=42

N=28

N=23

N=42

Cost
I will spend $15 to $500 a month
on long-term treatments.
Cost will not influence my choice
of treatment.

76.2

0.0

95.7

61.9

21.4

85.7

4.3

33.3

2.4

14.3

0.0

4.8

X2

p

58.66

<.001

20.77

.002

9.21

NS

I will spend over $1200 a month
on treatment if it is less than 6
months
Insurance Coverage
I will only use treatment options
that are covered by insurance
Insurance coverage may influence
my choice
Insurance coverage will not
influence my choice.

23.8

0.0

17.4

4.8

64.3

64.3

69.6

85.7

11.9

35.7

13.0

9.5

Scientific Validity
Table 1 Continued…
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Variable
Strong scientific validity
Scientific validity may or may not
influence my choice
I will not care about scientific
validity

Cluster 1

Cluster 2

Cluster 3

Cluster 4

N=42

N=28

N=23

N=42

78.6

78.6

69.6

59.5

21.4

17.9

30.4

40.5

0.0

3.6

0.0

0.0

Sessions with Provider
Weekly sessions with provider

4.8

17.9

13.0

38.1

Some sessions with provider

90.5

67.9

56.5

57.8

Minimal sessions with provider

4.8

14.3

30.4

7.1

Therapeutic Component
Does not matter if treatment has
therapeutic component
Would like it included but not
required
Therapeutic component required

0.0

14.3

39.1

9.5

95.2

53.6

52.2

35.7

4.8

32.1

8.7

54.8

Immediate Changes
Table 1 Continued…
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X2

p

26.79

<.001

54.69

<.001

35.24

<.001

Variable
Immediate changes in behavior
are important

Cluster 1

Cluster 2

Cluster 3

Cluster 4

N=42

N=28

N=23

N=42

26.2

32.1

65.2

0.0

71.4

60.7

30.4

95.2

2.4

7.1

4.3

4.8

X2

p

13.78

.032

Immediate changes are not
important if there is reassurance
of behavior changes
Immediate changes in behavior
are not important
Continuation of Treatment
No more treatment when
symptoms are no longer

66.7

53.6

39.1

33.3

26.2

21.4

30.4

42.9

7.1

25.0

30.4

23.8

observed
Not important if treatment
continues after symptoms are no
longer observed
Important to continue to need
treatment

Table 1 Continued…
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Variable

Cluster 1

Cluster 2

Cluster 3

Cluster 4

N=42

N=28

N=23

N=42

Awareness of Condition
Treatment to keep child unaware
of condition
Not important for child to be
aware of condition
Treatment to help child be aware
of condition

0.0

7.1

4.3

0.0

14.3

7.1

0.0

19.0

85.7

85.7

95.7

81.0

Medication Treatment
No medication

0.0

25.0

0.0

14.3

Low dose of medication

92.9

53.6

65.2

73.8

High dose of medication

7.1

21.4

34.8

11.9

Brain-based Treatment
No brain-based treatment
Some sessions of brain-based
treatment
40 sessions of brain-based
treatment

26.2

35.7

95.7

16.7

66.7

53.6

4.3

69.0

7.1

10.7

0.0

14.3
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X2

p

11.05

NS

25.84

<.001

44.55

<.001
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